<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20031101//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">2928273</article-id><article-id pub-id-type="pmid">20811626</article-id><article-id pub-id-type="publisher-id">10-PONE-RA-17637R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0012402</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Oncology</subject><subject>Genetics and Genomics/Genetics of the Immune System</subject><subject>Oncology/Lung Cancer</subject><subject>Oncology/Oncology Agents</subject></subj-group></article-categories><title-group><article-title>Genetic Variants in Inflammation-Related Genes Are Associated with Radiation-Induced Toxicity Following Treatment for Non-Small Cell Lung Cancer</article-title><alt-title alt-title-type="running-head">NSCLC Radiation Toxicity</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hildebrandt</surname><given-names>Michelle A. T.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Komaki</surname><given-names>Ritsuko</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Liao</surname><given-names>Zhongxing</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Gu</surname><given-names>Jian</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chang</surname><given-names>Joe Y.</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ye</surname><given-names>Yuanqing</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Charles</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Stewart</surname><given-names>David J.</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Minna</surname><given-names>John D.</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Roth</surname><given-names>Jack A.</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lippman</surname><given-names>Scott M.</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Cox</surname><given-names>James D.</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hong</surname><given-names>Waun Ki</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Spitz</surname><given-names>Margaret R.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Xifeng</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>&#x0002a;</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America</addr-line>
</aff><aff id="aff4">
<label>4</label>
<addr-line>Hamon Center for Therapeutic Oncology Research, The University of Texas Southwestern Medical Center, Dallas, Texas, United States of America</addr-line>
</aff><aff id="aff5">
<label>5</label>
<addr-line>Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Cordes</surname><given-names>Nils</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Dresden University of Technology, Germany</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>xwu@mdanderson.org</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: MATH XW. Performed the experiments: JG. Analyzed the data: MATH YY. Contributed reagents/materials/analysis tools: RK ZL JG JYC YY CL DJS JDM JAR SL JDC WKH MRS XW. Wrote the paper: MATH XW.</p></fn></author-notes><pub-date pub-type="collection"><year>2010</year></pub-date><pub-date pub-type="epub"><day>25</day><month>8</month><year>2010</year></pub-date><volume>5</volume><issue>8</issue><elocation-id>e12402</elocation-id><history><date date-type="received"><day>23</day><month>3</month><year>2010</year></date><date date-type="accepted"><day>2</day><month>8</month><year>2010</year></date></history><permissions><copyright-statement>Hildebrandt et al.</copyright-statement><copyright-year>2010</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><p>Treatment of non-small cell lung cancer (NSCLC) with radiotherapy or chemoradiotherapy is often accompanied by the development of esophagitis and pneumonitis. Identifying patients who might be at increased risk for normal tissue toxicity would help in determination of the optimal radiation dose to avoid these events. We profiled 59 single nucleotide polymorphisms (SNPs) from 37 inflammation-related genes in 173 NSCLC patients with stage IIIA/IIIB (dry) disease who were treated with definitive radiation or chemoradiation. For esophagitis risk, nine SNPs were associated with a 1.5- to 4-fold increase in risk, including three <italic>PTGS2</italic> (COX2) variants: rs20417 (HR:1.93, 95&#x00025; CI:1.10&#x02013;3.39), rs5275 (HR:1.58, 95&#x00025; CI:1.09&#x02013;2.27), and rs689470 (HR:3.38, 95&#x00025; CI:1.09&#x02013;10.49). Significantly increased risk of pneumonitis was observed for patients with genetic variation in the proinflammatory genes <italic>IL1A</italic>, <italic>IL8</italic>, <italic>TNF</italic>, <italic>TNFRSF1B</italic>, and <italic>MIF</italic>. In contrast, NOS3:rs1799983 displayed a protective effect with a 45&#x00025; reduction in pneumonitis risk (HR:0.55, 95&#x00025; CI:0.31&#x02013;0.96). Pneumonitis risk was also modulated by polymorphisms in anti-inflammatory genes, including genetic variation in <italic>IL13</italic>. rs20541 and rs180925 each resulted in increased risk (HR:2.95, 95&#x00025; CI:1.14&#x02013;7.63 and HR:3.23, 95&#x00025; CI:1.03&#x02013;10.18, respectively). The cumulative effect of these SNPs on risk was dose-dependent, as evidenced by a significantly increased risk of either toxicity with an increasing number of risk genotypes (<italic>P</italic>&#x0003c;0.001). These results suggest that genetic variations among inflammation pathway genes may modulate the development of radiation-induced toxicity and, ultimately, help in identifying patients who are at an increased likelihood for such events.</p></abstract><counts><page-count count="11"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>It was predicted that lung cancer would be diagnosed in over 215,000 individuals in the United States alone in 2008 <xref rid="pone.0012402-Jemal1" ref-type="bibr">[1]</xref>. Patients with locally advanced stage IIIA and IIIB (dry) disease who are not candidates for surgery are treated with definitive radiation therapy or combination chemoradiation therapy <xref rid="pone.0012402-Spira1" ref-type="bibr">[2]</xref>. Unfortunately even with treatment, the overall 5-year survival rate for NSCLC patients is only 10&#x02013;15&#x00025; <xref rid="pone.0012402-Greenlee1" ref-type="bibr">[3]</xref>.</p><p>One of the challenges in lung cancer treatment with radiotherapy is the development of severe dose-limiting side effects. Esophagitis and pneumonitis are common acute radiation-induced normal tissue toxicities occurring in patients within one year following treatment. Presence of these toxicities can also cause a reduction in quality of life and may lead to chronic complications including lung fibrosis <xref rid="pone.0012402-Rubin1" ref-type="bibr">[4]</xref>. Currently, there are few predictors for the development of these toxicities based on clinical and dosimetric parameters <xref rid="pone.0012402-Robnett1" ref-type="bibr">[5]</xref>&#x02013;<xref rid="pone.0012402-Wang1" ref-type="bibr">[9]</xref>. Therefore, the identification of additional reliable markers could help to tailor radiation regimens in order to administer the optimal therapeutic dose while minimizing toxicity.</p><p>Inflammation is a physiological response to cellular and tissue damage, including radiation-induced damage. Appropriate response to this damage is tightly regulated through a balance between proinflammatory and anti-inflammatory cytokines and signaling molecules <xref rid="pone.0012402-Dinarello1" ref-type="bibr">[10]</xref>, <xref rid="pone.0012402-Opal1" ref-type="bibr">[11]</xref>. Genetic variation in key inflammation-related genes may cause a shift in balance resulting in deregulation of the inflammatory response and corresponding modulation of susceptibility to radiation-induced normal tissue damage <xref rid="pone.0012402-Barnett1" ref-type="bibr">[12]</xref>. Previous studies have investigated genetic variation in transforming growth factor-beta 1 (TGF-&#x003b2;1). This important cytokine is up regulated following radiation exposure and common variants located in <italic>TGFB1</italic> have been found to be associated with late normal tissue complications <xref rid="pone.0012402-Andreassen1" ref-type="bibr">[13]</xref>&#x02013;<xref rid="pone.0012402-Quarmby1" ref-type="bibr">[17]</xref>.</p><p>In this study, we utilized a pathway-based approach to analyze genetic variation from 59 SNPs in 37 inflammation-related genes with regard to risk of developing either acute esophagitis or pneumonitis following radiation therapy. We explored the main effects of single SNPs and also the cumulative effect of genetic variation within the inflammation pathway on toxicity risk. These results indicate that an individual's risk of developing these severe side effects may be modulated by germline variation in inflammation genes and may help to personalize radiation therapy for NSCLC.</p></sec><sec id="s2"><title>Results</title><sec id="s2a"><title>Patient Characteristics</title><p>A total of 173 non-Hispanic Caucasian patients with stage IIIA (n&#x0200a;=&#x0200a;70 or 40.5&#x00025;) or IIIB (dry) (n&#x0200a;=&#x0200a;103 or 59.5&#x00025;) were included in the analysis (<xref ref-type="table" rid="pone-0012402-t001">
<bold>Table 1</bold>
</xref>). Of these patients, 91 (52.6&#x00025;) were men and 82 (47.4&#x00025;) were women with a median age of 63.6 years. Most of the patients had a history of smoking with 46.8&#x00025; (n&#x0200a;=&#x0200a;81) being former smokers and 46.2&#x00025; (n&#x0200a;=&#x0200a;80) currently smoking or having quit within a year prior to diagnosis. Sixty-three (36.4&#x00025;) of the tumors were classified as squamous cell carcinoma, 59 (34.1&#x00025;) as adenocarcinoma, and 40 (23.1&#x00025;) as non-small cell carcinoma, with the remainder (11 or 6.4&#x00025;) as other NSCLC. Twenty-two patients were given a pre-treatment ECOG performance score &#x02265;2. Nearly 80&#x00025; (n&#x0200a;=&#x0200a;138) of the patients received combination chemoradiation therapy, primarily with cisplatin or carboplatin (n&#x0200a;=&#x0200a;142). A majority were treated with 3D radiotherapy (n&#x0200a;=&#x0200a;72 or 41.6&#x00025;). There were 78 occurrences of grade &#x02265;2 esophagitis and 43 of grade &#x02265;2 pneumonitis in our population. Twenty-three of these patients had both esophagitis and pneumonitis, while 75 patients had neither.</p><table-wrap id="pone-0012402-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0012402.t001</object-id><label>Table 1</label><caption><title>Patient characteristics.</title></caption><alternatives><graphic id="pone-0012402-t001-1" xlink:href="pone.0012402.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td colspan="3" align="left" rowspan="1">Esophagitis</td><td colspan="3" align="left" rowspan="1">Pneumonitis</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Overall</td><td align="left" rowspan="1" colspan="1">Grade &#x0003c;2 n(&#x00025;)</td><td align="left" rowspan="1" colspan="1">Grade &#x02265;2 n(&#x00025;)</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic> value</td><td align="left" rowspan="1" colspan="1">Grade &#x0003c;2 n(&#x00025;)</td><td align="left" rowspan="1" colspan="1">Grade &#x02265;2 n(&#x00025;)</td><td align="left" rowspan="1" colspan="1">
<italic>P v</italic>alue</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Gender</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">91</td><td align="left" rowspan="1" colspan="1">50(52.63)</td><td align="left" rowspan="1" colspan="1">41(52.56)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">73(56.15)</td><td align="left" rowspan="1" colspan="1">18(41.86)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">82</td><td align="left" rowspan="1" colspan="1">45(47.37)</td><td align="left" rowspan="1" colspan="1">37(47.44)</td><td align="left" rowspan="1" colspan="1">0.993</td><td align="left" rowspan="1" colspan="1">57(43.85)</td><td align="left" rowspan="1" colspan="1">25(58.14)</td><td align="left" rowspan="1" colspan="1">0.104</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">173</td><td align="left" rowspan="1" colspan="1">95</td><td align="left" rowspan="1" colspan="1">78</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">130</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Age, mean(SD)</bold>
</td><td align="left" rowspan="1" colspan="1">63.60(9.98)</td><td align="left" rowspan="1" colspan="1">64.85(10.14)</td><td align="left" rowspan="1" colspan="1">62.08(9.64)</td><td align="left" rowspan="1" colspan="1">0.069</td><td align="left" rowspan="1" colspan="1">64.18(10.02)</td><td align="left" rowspan="1" colspan="1">61.86(9.78)</td><td align="left" rowspan="1" colspan="1">0.188</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Smoking status</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Never</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">6(6.32)</td><td align="left" rowspan="1" colspan="1">6(7.69)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">8(6.15)</td><td align="left" rowspan="1" colspan="1">4(9.30)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Former</td><td align="left" rowspan="1" colspan="1">81</td><td align="left" rowspan="1" colspan="1">47(49.47)</td><td align="left" rowspan="1" colspan="1">34(43.59)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">53(40.77)</td><td align="left" rowspan="1" colspan="1">28(65.12)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Current &#x00026; Recent Quitter</td><td align="left" rowspan="1" colspan="1">80</td><td align="left" rowspan="1" colspan="1">42(44.21)</td><td align="left" rowspan="1" colspan="1">38(48.72)</td><td align="left" rowspan="1" colspan="1">0.733</td><td align="left" rowspan="1" colspan="1">69(53.08)</td><td align="left" rowspan="1" colspan="1">11(25.58)</td><td align="left" rowspan="1" colspan="1">
<bold>0.007</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">173</td><td align="left" rowspan="1" colspan="1">95</td><td align="left" rowspan="1" colspan="1">78</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">130</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Packyr, mean(SD)</bold>
</td><td align="left" rowspan="1" colspan="1">51.62(28.67)</td><td align="left" rowspan="1" colspan="1">53.67(28.37)</td><td align="left" rowspan="1" colspan="1">49.08(29.04)</td><td align="left" rowspan="1" colspan="1">0.315</td><td align="left" rowspan="1" colspan="1">53.71(29.41)</td><td align="left" rowspan="1" colspan="1">45.07(25.48)</td><td align="left" rowspan="1" colspan="1">0.102</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Histology</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Adenocarcinoma</td><td align="left" rowspan="1" colspan="1">59</td><td align="left" rowspan="1" colspan="1">26(27.37)</td><td align="left" rowspan="1" colspan="1">33(42.31)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">42(32.31)</td><td align="left" rowspan="1" colspan="1">17(39.53)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Squamous Cell Carcinoma</td><td align="left" rowspan="1" colspan="1">63</td><td align="left" rowspan="1" colspan="1">41(43.16)</td><td align="left" rowspan="1" colspan="1">22(28.21)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">48(36.92)</td><td align="left" rowspan="1" colspan="1">15(34.88)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Non-small Cell Carcinoma</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">21(22.11)</td><td align="left" rowspan="1" colspan="1">19(24.36)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">33(25.38)</td><td align="left" rowspan="1" colspan="1">7(16.28)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Other NSCLC</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">7(7.37)</td><td align="left" rowspan="1" colspan="1">4(5.13)</td><td align="left" rowspan="1" colspan="1">0.118</td><td align="left" rowspan="1" colspan="1">7(5.38)</td><td align="left" rowspan="1" colspan="1">4(9.30)</td><td align="left" rowspan="1" colspan="1">0.481</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">173</td><td align="left" rowspan="1" colspan="1">95</td><td align="left" rowspan="1" colspan="1">78</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">130</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Clinical stage</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Stage IIIA</td><td align="left" rowspan="1" colspan="1">70</td><td align="left" rowspan="1" colspan="1">41(43.16)</td><td align="left" rowspan="1" colspan="1">29(37.18)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">46(35.38)</td><td align="left" rowspan="1" colspan="1">24(55.81)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Stage IIB(dry)</td><td align="left" rowspan="1" colspan="1">103</td><td align="left" rowspan="1" colspan="1">54(56.84)</td><td align="left" rowspan="1" colspan="1">49(62.82)</td><td align="left" rowspan="1" colspan="1">0.425</td><td align="left" rowspan="1" colspan="1">84(64.62)</td><td align="left" rowspan="1" colspan="1">19(44.19)</td><td align="left" rowspan="1" colspan="1">
<bold>0.018</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">173</td><td align="left" rowspan="1" colspan="1">95</td><td align="left" rowspan="1" colspan="1">78</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">130</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Performance status</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">52</td><td align="left" rowspan="1" colspan="1">23(24.21)</td><td align="left" rowspan="1" colspan="1">29(37.18)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">38(29.23)</td><td align="left" rowspan="1" colspan="1">14(32.56)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">99</td><td align="left" rowspan="1" colspan="1">59(62.11)</td><td align="left" rowspan="1" colspan="1">40(51.28)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">75(57.69)</td><td align="left" rowspan="1" colspan="1">24(55.81)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">2&#x02013;4</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">13(13.68)</td><td align="left" rowspan="1" colspan="1">9(11.54)</td><td align="left" rowspan="1" colspan="1">0.180</td><td align="left" rowspan="1" colspan="1">17(13.08)</td><td align="left" rowspan="1" colspan="1">5(11.63)</td><td align="left" rowspan="1" colspan="1">0.908</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">173</td><td align="left" rowspan="1" colspan="1">95</td><td align="left" rowspan="1" colspan="1">78</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">130</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Treatment</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Radiation</td><td align="left" rowspan="1" colspan="1">35</td><td align="left" rowspan="1" colspan="1">31(32.63)</td><td align="left" rowspan="1" colspan="1">4(5.13)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">29(22.31)</td><td align="left" rowspan="1" colspan="1">6(13.95)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Chemoradiation</td><td align="left" rowspan="1" colspan="1">138</td><td align="left" rowspan="1" colspan="1">64(67.37)</td><td align="left" rowspan="1" colspan="1">74(94.87)</td><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td><td align="left" rowspan="1" colspan="1">101(77.69)</td><td align="left" rowspan="1" colspan="1">37(86.05)</td><td align="left" rowspan="1" colspan="1">0.237</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">173</td><td align="left" rowspan="1" colspan="1">95</td><td align="left" rowspan="1" colspan="1">78</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">130</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Radiation type</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">2D</td><td align="left" rowspan="1" colspan="1">55</td><td align="left" rowspan="1" colspan="1">36(37.89)</td><td align="left" rowspan="1" colspan="1">19(24.36)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">47(36.15)</td><td align="left" rowspan="1" colspan="1">8(18.60)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">3D</td><td align="left" rowspan="1" colspan="1">72</td><td align="left" rowspan="1" colspan="1">29(30.53)</td><td align="left" rowspan="1" colspan="1">43(55.13)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">46(35.38)</td><td align="left" rowspan="1" colspan="1">26(60.47)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">IMRT</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">30(31.58)</td><td align="left" rowspan="1" colspan="1">16(20.51)</td><td align="left" rowspan="1" colspan="1">
<bold>0.005</bold>
</td><td align="left" rowspan="1" colspan="1">37(28.46)</td><td align="left" rowspan="1" colspan="1">9(20.93)</td><td align="left" rowspan="1" colspan="1">
<bold>0.013</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">173</td><td align="left" rowspan="1" colspan="1">95</td><td align="left" rowspan="1" colspan="1">78</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">130</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Radiation dose, mean(SD)</bold>
</td><td align="left" rowspan="1" colspan="1">62.34(10.40)</td><td align="left" rowspan="1" colspan="1">60.75(12.64)</td><td align="left" rowspan="1" colspan="1">64.27(6.29)</td><td align="left" rowspan="1" colspan="1">
<bold>0.026</bold>
</td><td align="left" rowspan="1" colspan="1">61.68(11.63)</td><td align="left" rowspan="1" colspan="1">64.32(4.66)</td><td align="left" rowspan="1" colspan="1">0.149</td></tr></tbody></table></alternatives></table-wrap><p>There were no significant differences between patients who developed severe esophagitis and those who did not with regard to age, gender, smoking status, histology, clinical stage and performance status. However, patients who developed esophagitis were more likely to receive chemoradiation instead of radiation alone (<italic>P</italic>&#x0003c;0.001), and more likely to receive a higher mean radiation dose (<italic>P</italic>&#x0200a;=&#x0200a;0.026) compared to those who did not develop esophagitis. Interestingly, severe pneumonitis was more frequent in patients who were former smokers compared to current smokers or recent quitters (<italic>P</italic>&#x0200a;=&#x0200a;0.007). Patients with stage IIIA patients were also more likely to develop pneumonitis (<italic>P</italic>&#x0200a;=&#x0200a;0.018). For both esophagitis and pneumonitis, there was a significant difference in the occurrence of toxicity by the type of radiation therapy administered (<italic>P</italic>&#x0200a;=&#x0200a;0.005 and 0.013, respectively).</p></sec><sec id="s2b"><title>Inflammation-related SNPs and Risk of Esophagitis</title><p>Among the 59 SNPs studied, a total of nine inflammation-related SNPs were found to be significantly associated with risk of esophagitis following radiation treatment (<xref ref-type="table" rid="pone-0012402-t002">
<bold>Table 2</bold>
</xref>). All of these variants remained significant at an FDR level of 10&#x00025;. In addition, because esophagitis typically presents 4&#x02013;6 weeks following initiation of radiation therapy, we also analyzed the effect of these variants using logistic regression. The results are similar to those from the Cox regression analysis (data not shown).</p><table-wrap id="pone-0012402-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0012402.t002</object-id><label>Table 2</label><caption><title>Inflammation-related SNPs and risk of esophagitis.</title></caption><alternatives><graphic id="pone-0012402-t002-2" xlink:href="pone.0012402.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Grade &#x0003c;2 n(&#x00025;)</td><td align="left" rowspan="1" colspan="1">Grade &#x02265;2 n(&#x00025;)</td><td align="left" rowspan="1" colspan="1">
<xref ref-type="table-fn" rid="nt101">&#x0002a;</xref>HR</td><td align="left" rowspan="1" colspan="1">95&#x00025; CI</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic> value</td><td align="left" rowspan="1" colspan="1">Q value</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Grade &#x0003c;2 n(&#x00025;)</td><td align="left" rowspan="1" colspan="1">Grade &#x02265;2 n(&#x00025;)</td><td align="left" rowspan="1" colspan="1">
<xref ref-type="table-fn" rid="nt101">&#x0002a;</xref>HR</td><td align="left" rowspan="1" colspan="1">95&#x00025; CI</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic> value</td><td align="left" rowspan="1" colspan="1">Q value</td></tr></thead><tbody><tr><td colspan="13" align="left" rowspan="1">
<bold><italic>Proinflammatory cytokines, receptors, and related molecules</italic></bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>IL6:rs1800795</bold>
</td><td align="left" rowspan="1" colspan="1">94</td><td align="left" rowspan="1" colspan="1">76</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>PTGS2:rs20417</bold>
</td><td align="left" rowspan="1" colspan="1">94</td><td align="left" rowspan="1" colspan="1">76</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">32(34.0)</td><td align="left" rowspan="1" colspan="1">30(39.5)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GG</td><td align="left" rowspan="1" colspan="1">82(87.2)</td><td align="left" rowspan="1" colspan="1">54(71.1)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CG</td><td align="left" rowspan="1" colspan="1">53(56.4)</td><td align="left" rowspan="1" colspan="1">27(35.5)</td><td align="left" rowspan="1" colspan="1">0.67</td><td align="left" rowspan="1" colspan="1">0.38 to 1.18</td><td align="left" rowspan="1" colspan="1">0.162</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GC</td><td align="left" rowspan="1" colspan="1">
<bold>12(12.8)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>20(26.3)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.90</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.07 to 3.39</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.029</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">GG</td><td align="left" rowspan="1" colspan="1">9(9.6)</td><td align="left" rowspan="1" colspan="1">19(25.0)</td><td align="left" rowspan="1" colspan="1">1.70</td><td align="left" rowspan="1" colspan="1">0.87 to 3.35</td><td align="left" rowspan="1" colspan="1">0.123</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">0(0.0)</td><td align="left" rowspan="1" colspan="1">2(2.6)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CC&#x0002b;CG vs. GG</td><td align="left" rowspan="1" colspan="1">
<bold>85</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>57</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>2.16</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.18 to 3.94</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.013</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.052</bold>
</td><td align="left" rowspan="1" colspan="1">GC&#x0002b;CC</td><td align="left" rowspan="1" colspan="1">
<bold>12</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>22</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.93</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.10 to 3.39</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.029</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.052</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>IL16:rs11556218</bold>
</td><td align="left" rowspan="1" colspan="1">96</td><td align="left" rowspan="1" colspan="1">75</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>PTGS2:rs5275</bold>
</td><td align="left" rowspan="1" colspan="1">92</td><td align="left" rowspan="1" colspan="1">75</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">TT</td><td align="left" rowspan="1" colspan="1">58(60.4)</td><td align="left" rowspan="1" colspan="1">41(54.7)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">TT</td><td align="left" rowspan="1" colspan="1">51(55.4)</td><td align="left" rowspan="1" colspan="1">32(42.7)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">TG</td><td align="left" rowspan="1" colspan="1">32(33.3)</td><td align="left" rowspan="1" colspan="1">22(29.3)</td><td align="left" rowspan="1" colspan="1">0.86</td><td align="left" rowspan="1" colspan="1">0.49 to 1.53</td><td align="left" rowspan="1" colspan="1">0.615</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">TC</td><td align="left" rowspan="1" colspan="1">39(42.4)</td><td align="left" rowspan="1" colspan="1">33(44.0)</td><td align="left" rowspan="1" colspan="1">1.43</td><td align="left" rowspan="1" colspan="1">0.85 to 2.39</td><td align="left" rowspan="1" colspan="1">0.178</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">GG</td><td align="left" rowspan="1" colspan="1">
<bold>6(6.3)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>12(16.0)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>2.14</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.05 to 4.36</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.035</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">
<bold>2(2.2)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>10(13.3)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>2.71</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.25 to 5.88</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.011</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">TT&#x0002b;TG vs. GG</td><td align="left" rowspan="1" colspan="1">
<bold>90</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>63</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>2.28</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.16 to 4.47</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.017</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.052</bold>
</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic> for trend</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>1.58</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.09 to 2.27</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.014</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.052</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>TNF:rs1799724</bold>
</td><td align="left" rowspan="1" colspan="1">92</td><td align="left" rowspan="1" colspan="1">71</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>PTGS2:rs689470</bold>
</td><td align="left" rowspan="1" colspan="1">96</td><td align="left" rowspan="1" colspan="1">74</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">74(80.4)</td><td align="left" rowspan="1" colspan="1">50(70.4)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">92(72.3)</td><td align="left" rowspan="1" colspan="1">70(94.6)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CT</td><td align="left" rowspan="1" colspan="1">
<bold>12(13.0)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>20(28.2)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>2.13</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.17 to 3.86</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.013</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CT</td><td align="left" rowspan="1" colspan="1">4(4.2)</td><td align="left" rowspan="1" colspan="1">3(4.1)</td><td align="left" rowspan="1" colspan="1">2.67</td><td align="left" rowspan="1" colspan="1">0.73 to 9.96</td><td align="left" rowspan="1" colspan="1">0.136</td><td align="left" rowspan="1" colspan="1">
<bold>0.072</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">TT</td><td align="left" rowspan="1" colspan="1">6(6.5)</td><td align="left" rowspan="1" colspan="1">1(1.4)</td><td align="left" rowspan="1" colspan="1">0.91</td><td align="left" rowspan="1" colspan="1">0.12 to 6.99</td><td align="left" rowspan="1" colspan="1">0.928</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">TT</td><td align="left" rowspan="1" colspan="1">0(0.0)</td><td align="left" rowspan="1" colspan="1">1(1.4)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CT&#x0002b;TT</td><td align="left" rowspan="1" colspan="1">
<bold>18</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>21</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.97</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.10 to 3.50</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.022</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.052</bold>
</td><td align="left" rowspan="1" colspan="1">CT&#x0002b;TT</td><td align="left" rowspan="1" colspan="1">
<bold>4</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>4</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>3.38</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.09 to 10.49</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.035</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="13" align="left" rowspan="1">
<bold><italic>Anti-inflammatory cytokines, receptors, and related molecules</italic></bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>IL4R:rs1801275</bold>
</td><td align="left" rowspan="1" colspan="1">94</td><td align="left" rowspan="1" colspan="1">75</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>IL10RA:rs3135932</bold>
</td><td align="left" rowspan="1" colspan="1">95</td><td align="left" rowspan="1" colspan="1">76</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">AA</td><td align="left" rowspan="1" colspan="1">60(63.8)</td><td align="left" rowspan="1" colspan="1">40(53.3)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AA</td><td align="left" rowspan="1" colspan="1">68(71.6)</td><td align="left" rowspan="1" colspan="1">43(56.6)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">AG</td><td align="left" rowspan="1" colspan="1">34(36.2)</td><td align="left" rowspan="1" colspan="1">28(37.3)</td><td align="left" rowspan="1" colspan="1">0.99</td><td align="left" rowspan="1" colspan="1">0.58 to 1.68</td><td align="left" rowspan="1" colspan="1">0.973</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AG</td><td align="left" rowspan="1" colspan="1">24(25.3)</td><td align="left" rowspan="1" colspan="1">28(36.8)</td><td align="left" rowspan="1" colspan="1">1.38</td><td align="left" rowspan="1" colspan="1">0.83 to 2.28</td><td align="left" rowspan="1" colspan="1">0.217</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">GG</td><td align="left" rowspan="1" colspan="1">0(0.0)</td><td align="left" rowspan="1" colspan="1">7(9.3)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GG</td><td align="left" rowspan="1" colspan="1">3(3.2)</td><td align="left" rowspan="1" colspan="1">5(6.6)</td><td align="left" rowspan="1" colspan="1">2.60</td><td align="left" rowspan="1" colspan="1">0.99 to 9.83</td><td align="left" rowspan="1" colspan="1">0.053</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">AA&#x0002b;AG vs. GG</td><td align="left" rowspan="1" colspan="1">
<bold>94</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>68</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>4.12</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.60 to 10.59</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.003</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.052</bold>
</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic> for trend</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>1.49</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.01 to 2.20</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.046</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.083</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>IL10:rs1800872</bold>
</td><td align="left" rowspan="1" colspan="1">94</td><td align="left" rowspan="1" colspan="1">75</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">65(69.1)</td><td align="left" rowspan="1" colspan="1">43(57.3)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CA</td><td align="left" rowspan="1" colspan="1">27(28.7)</td><td align="left" rowspan="1" colspan="1">26(34.7)</td><td align="left" rowspan="1" colspan="1">1.59</td><td align="left" rowspan="1" colspan="1">0.93 to 2.72</td><td align="left" rowspan="1" colspan="1">0.093</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">AA</td><td align="left" rowspan="1" colspan="1">
<bold>2(2.1)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>6(8.0)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>2.88</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.15 to 7.22</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.024</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>P</italic> for trend</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>1.65</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.11 to 2.45</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.013</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.052</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>&#x0002a;adjusted for age, gender, pack years, clinical stage, performance status, treatment regimen, radiation type, and radiation dosage.</p></fn></table-wrap-foot></table-wrap><sec id="s2b1"><title>Proinflammatory Genes</title><p>Of these nine SNPs, six were among genes involved in the proinflammatory response: <italic>IL6</italic>, <italic>IL16</italic>, <italic>TNF</italic>, and <italic>PTGS2</italic> (COX2). Interleukin 6 (IL6):rs1800795 resulted in an 2.16-fold increased risk (95&#x00025; CI:1.18&#x02013;3.94) under the recessive model. A similar effect was observed for IL16:rs11556218 (HR:2.28, 95&#x00025; CI:1.16&#x02013;4.47). Patients with at least one tumor necrosis factor-&#x003b1; (TNF) variant rs1799724 had a nearly 2-fold increased risk (HR:1.97, 95&#x00025; CI:1.10&#x02013;3.50). Three SNPs in <italic>PTGS2</italic> modulated esophagitis risk in our patient population: rs20417, rs5275, and rs689470. PTGS2:rs5275 was associated with an increased risk (<italic>P</italic> for trend &#x0200a;=&#x0200a;0.014). For rs20417 and rs689470, carriers of at least one variant allele were at an increased risk (HR:1.93, 95&#x00025; CI:1.10&#x02013;3.39 and HR:3.38, 95&#x00025; CI:1.09&#x02013;10.49, respectively).</p></sec><sec id="s2b2"><title>Anti-inflammatory Genes</title><p>SNPs in the IL4 receptor, IL10, and the alpha subunit of the IL10 receptor were found to be significantly associated with increased esophagitis risk. The IL10:rs1800872 and IL10RA:rs3135932 variants were both associated with significantly increased risks under the additive model with HRs of 1.65 (95&#x00025; CI: 1.11&#x02013;2.45) and 1.49 (95&#x00025; CI: 1.01&#x02013;2.20), respectively. IL4R:rs1801275 resulted in over a 4-fold increased risk (HR:4.12, 95&#x00025; CI:1.60&#x02013;10.59).</p></sec><sec id="s2b3"><title>Joint Analysis of Esophagitis Risk Alleles</title><p>To understand the cumulative effect of unfavorable genotypes on risk of esophagitis, we performed a combined analysis. We included all significant SNPs identified from our individual SNP analysis and an additional seven SNPs reaching borderline significance at p&#x0003c;0.10 (<xref ref-type="table" rid="pone-0012402-t003">
<bold>Table 3</bold>
</xref>). Patients with four unfavorable genotypes had a 3.71-fold increased risk (95&#x00025; CI:1.53&#x02013;8.99) compared to those with 0&#x0223c;3 unfavorable genotypes. This risk increased to 8.85 (95&#x00025; CI:4.19&#x02013;18.68) for patients with five or more unfavorable genotypes. Furthermore, patients with an increasing number of unfavorable genotypes developed esophagitis significantly quicker following initiation of radiation therapy (<xref ref-type="fig" rid="pone-0012402-g001">
<bold>Figure 1A</bold>
</xref>). Carriers of five or more unfavorable genotypes had a median time to event of only 1.1 months compared to over 12 months for those with three or less unfavorable genotypes (<italic>P</italic>&#x0003c;0.0001).</p><fig id="pone-0012402-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0012402.g001</object-id><label>Figure 1</label><caption><title>Event-free survival by number of unfavorable genotypes in inflammation-related genes.</title><p>Kaplan-Meier curves of freedom from (<bold>A</bold>) grade &#x0003e;2 esophagitis or (<bold>B</bold>) grade &#x0003e;2 pneumonitis following radiation therapy. Numbers in parentheses are the number of patients with toxicity over the total number of patients; time is median event-free duration in months.</p></caption><graphic xlink:href="pone.0012402.g001"/></fig><table-wrap id="pone-0012402-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0012402.t003</object-id><label>Table 3</label><caption><title>Cumulative effect of unfavorable genotypes and radiation-induced toxicity risk.</title></caption><alternatives><graphic id="pone-0012402-t003-3" xlink:href="pone.0012402.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Number of Unfavorable Genotypes</td><td align="left" rowspan="1" colspan="1">Grade &#x0003c;2 n</td><td align="left" rowspan="1" colspan="1">Grade &#x02265;2 n</td><td align="left" rowspan="1" colspan="1">
<xref ref-type="table-fn" rid="nt102">&#x0002a;</xref>HR</td><td align="left" rowspan="1" colspan="1">95&#x00025; CI</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic> value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold><sup>#</sup>Esophagitis</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">0&#x0223c;3</td><td align="left" rowspan="1" colspan="1">49</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">23</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">
<bold>3.71</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.53 to 8.99</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.004</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;5</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">
<bold>8.85</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>4.19 to 18.68</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>P</italic> trend</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td></tr><tr><td colspan="6" align="left" rowspan="1">
<xref ref-type="table-fn" rid="nt107">&#x00026;</xref>
<bold>Phenumonitis</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">0&#x0223c;2</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">58</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">
<bold>13.30</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.72 to 102.94</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.013</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;4</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">
<bold>69.42</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>8.62 to 558.91</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>P</italic> trend</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt102"><label/><p>&#x0002a;adjusted for age, gender, pack years, clinical stage, performance status, treatment regimen,</p></fn><fn id="nt103"><label/><p>radiation type, and radiation dosage<bold>.</bold>
</p></fn><fn id="nt104"><label/><p>
<sup>#</sup>unfavorable genotypes: IL6:rs1800795, IL16:rs11556218, TNF:rs1799724, PTGS2:rs20417.</p></fn><fn id="nt105"><label/><p>PTGS2:rs5275, PTGS2:rs689470, IL4R:rs1801275, IL10:rs1800872, IL10RA:rs3135932.</p></fn><fn id="nt106"><label/><p>IL1B:rs16944, IL2RB:rs228942, IL8:rs4073, IL10RB:rs2834167, IL13:rs1800925, NOS2:rs2297518.</p></fn><fn id="nt107"><label>&#x00026;</label><p>unfavorable genotypes: IL1A:rs1800587, IL8:rs4073, TNF:rs1799724, TNFRSF1B:rs1061622.</p></fn><fn id="nt108"><label/><p>MIF:rs7555622, IL4:rs2243250, IL4R:rs2070874, IL13:rs10800925, IL13:rs20541, NOS3:rs1799983, NFKBIA:rs1799983.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s2c"><title>Inflammation-related SNPs and Risk of Pneumonitis</title><p>A different set of inflammation-related SNPs was found to be significantly associated with risk of developing pneumonitis following radiation therapy and remained so at an FDR of 10&#x00025; (<xref ref-type="table" rid="pone-0012402-t004">
<bold>Table 4</bold>
</xref>). Only one of the 12 SNPs identified were also associated with esophagitis risk &#x02013; TNF:rs1799724. Patients homozygous for this variant exhibited a 5.96-fold increased risk (95&#x00025; CI:1.33&#x02013;18.57) of pneumonitis. This risk is similar for esophagitis risk in patients carrying at least one variant allele (<xref ref-type="table" rid="pone-0012402-t002">
<bold>Table 2</bold>
</xref>).</p><table-wrap id="pone-0012402-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0012402.t004</object-id><label>Table 4</label><caption><title>Inflammation-related SNPs and risk of pneumonitis.</title></caption><alternatives><graphic id="pone-0012402-t004-4" xlink:href="pone.0012402.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Grade &#x0003c;2 n(&#x00025;)</td><td align="left" rowspan="1" colspan="1">Grade &#x02265;2 n(&#x00025;)</td><td align="left" rowspan="1" colspan="1">
<xref ref-type="table-fn" rid="nt109">&#x0002a;</xref>HR</td><td align="left" rowspan="1" colspan="1">95&#x00025; CI</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic> value</td><td align="left" rowspan="1" colspan="1">Q value</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Grade &#x0003c;2 n(&#x00025;)</td><td align="left" rowspan="1" colspan="1">Grade &#x02265;2 n(&#x00025;)</td><td align="left" rowspan="1" colspan="1">
<xref ref-type="table-fn" rid="nt109">&#x0002a;</xref>HR</td><td align="left" rowspan="1" colspan="1">95&#x00025; CI</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic> value</td><td align="left" rowspan="1" colspan="1">Q value</td></tr></thead><tbody><tr><td colspan="13" align="left" rowspan="1">
<bold><italic>Proinflammatory cytokines, receptors, and related molecules</italic></bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>IL1A:rs1800587</bold>
</td><td align="left" rowspan="1" colspan="1">128</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>TNFRSF1B:rs1061622</bold>
</td><td align="left" rowspan="1" colspan="1">126</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">65(50.8)</td><td align="left" rowspan="1" colspan="1">11(25.6)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">TT</td><td align="left" rowspan="1" colspan="1">72(57.1)</td><td align="left" rowspan="1" colspan="1">17(40.5)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CT</td><td align="left" rowspan="1" colspan="1">
<bold>51(39.8)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>30(69.8)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>3.66</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.66 to 8.07</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.001</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">TG</td><td align="left" rowspan="1" colspan="1">50(39.7)</td><td align="left" rowspan="1" colspan="1">22(52.4)</td><td align="left" rowspan="1" colspan="1">1.84</td><td align="left" rowspan="1" colspan="1">0.90 to 3.79</td><td align="left" rowspan="1" colspan="1">0.096</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">TT</td><td align="left" rowspan="1" colspan="1">12(9.4)</td><td align="left" rowspan="1" colspan="1">2(4.7)</td><td align="left" rowspan="1" colspan="1">0.89</td><td align="left" rowspan="1" colspan="1">0.19 to 4.23</td><td align="left" rowspan="1" colspan="1">0.885</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GG</td><td align="left" rowspan="1" colspan="1">
<bold>4(3.2)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>3(7.1)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>5.88</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.50 to 23.09</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.011</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CT&#x0002b;TT</td><td align="left" rowspan="1" colspan="1">
<bold>63</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>32</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>2.90</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.34 to 6.25</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.007</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.021</bold>
</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic> for trend</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>2.12</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.18 to 3.79</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.012</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.023</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>IL1A:rs17561</bold>
</td><td align="left" rowspan="1" colspan="1">128</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>MIF:rs755622</bold>
</td><td align="left" rowspan="1" colspan="1">126</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">GG</td><td align="left" rowspan="1" colspan="1">65(50.8)</td><td align="left" rowspan="1" colspan="1">12(27.9)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">89(70.6)</td><td align="left" rowspan="1" colspan="1">26(60.5)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">GT</td><td align="left" rowspan="1" colspan="1">
<bold>52(40.6)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>29(67.4)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>3.11</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.44 to 6.72</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.004</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CG</td><td align="left" rowspan="1" colspan="1">32(25.4)</td><td align="left" rowspan="1" colspan="1">12(27.9)</td><td align="left" rowspan="1" colspan="1">1.49</td><td align="left" rowspan="1" colspan="1">0.69 to 3.24</td><td align="left" rowspan="1" colspan="1">0.312</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">TT</td><td align="left" rowspan="1" colspan="1">11(8.6)</td><td align="left" rowspan="1" colspan="1">2(4.7)</td><td align="left" rowspan="1" colspan="1">0.85</td><td align="left" rowspan="1" colspan="1">0.18 to 4.01</td><td align="left" rowspan="1" colspan="1">0.836</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GG</td><td align="left" rowspan="1" colspan="1">
<bold>5(4.0)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>5(11.6)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>4.49</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.14 to 17.66</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.031</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">GT&#x0002b;TT</td><td align="left" rowspan="1" colspan="1">
<bold>63</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>31</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>2.51</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.19 to 5.27</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.015</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.024</bold>
</td><td align="left" rowspan="1" colspan="1">CC&#x0002b;CG vs. GG</td><td align="left" rowspan="1" colspan="1">
<bold>121</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>38</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>3.96</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.04 to 15.12</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.044</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.038</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>IL8:rs4073</bold>
</td><td align="left" rowspan="1" colspan="1">128</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>NOS3:rs1799983</bold>
</td><td align="left" rowspan="1" colspan="1">129</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">TT</td><td align="left" rowspan="1" colspan="1">37(28.9)</td><td align="left" rowspan="1" colspan="1">7(17.1)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GG</td><td align="left" rowspan="1" colspan="1">51(39.5)</td><td align="left" rowspan="1" colspan="1">22(52.4)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">TA</td><td align="left" rowspan="1" colspan="1">66(51.6)</td><td align="left" rowspan="1" colspan="1">19(46.3)</td><td align="left" rowspan="1" colspan="1">1.35</td><td align="left" rowspan="1" colspan="1">0.51 to 3.56</td><td align="left" rowspan="1" colspan="1">0.548</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GT</td><td align="left" rowspan="1" colspan="1">61(47.3)</td><td align="left" rowspan="1" colspan="1">17(40.5)</td><td align="left" rowspan="1" colspan="1">0.53</td><td align="left" rowspan="1" colspan="1">0.27 to 1.04</td><td align="left" rowspan="1" colspan="1">0.067</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">AA</td><td align="left" rowspan="1" colspan="1">
<bold>25(19.5)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>15(36.6)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>3.88</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.42 to 10.62</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.008</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">TT</td><td align="left" rowspan="1" colspan="1">17(13.2)</td><td align="left" rowspan="1" colspan="1">3(7.1)</td><td align="left" rowspan="1" colspan="1">0.34</td><td align="left" rowspan="1" colspan="1">0.08 to 1.51</td><td align="left" rowspan="1" colspan="1">0.157</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">TT&#x0002b;TA vs. AA</td><td align="left" rowspan="1" colspan="1">
<bold>103</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>26</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>3.16</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.54 to 6.48</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.002</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.010</bold>
</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic> for trend</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>0.55</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.31 to 0.96</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.037</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.038</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>TNF:rs1799724</bold>
</td><td align="left" rowspan="1" colspan="1">121</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">94(77.7)</td><td align="left" rowspan="1" colspan="1">30(71.4)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CT</td><td align="left" rowspan="1" colspan="1">23(19.0)</td><td align="left" rowspan="1" colspan="1">9(21.4)</td><td align="left" rowspan="1" colspan="1">1.45</td><td align="left" rowspan="1" colspan="1">0.64 to 3.26</td><td align="left" rowspan="1" colspan="1">0.370</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">TT</td><td align="left" rowspan="1" colspan="1">
<bold>4(3.3)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>3(7.1)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>5.32</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.40 to 20.22</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.014</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CC&#x0002b;CT vs. TT</td><td align="left" rowspan="1" colspan="1">
<bold>117</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>39</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>4.96</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.33 to 18.57</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.017</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.024</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="13" align="left" rowspan="1">
<bold><italic>Anti-inflammatory cytokines, receptors, and related molecules</italic></bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>IL4:rs2243250</bold>
</td><td align="left" rowspan="1" colspan="1">128</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>IL13:rs20541</bold>
</td><td align="left" rowspan="1" colspan="1">129</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">103(80.5)</td><td align="left" rowspan="1" colspan="1">27(64.3)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">88(68.2)</td><td align="left" rowspan="1" colspan="1">28(65.1)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CT</td><td align="left" rowspan="1" colspan="1">
<bold>22(17.2)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>13(31.0)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>2.50</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.22 to 5.11</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.012</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CT</td><td align="left" rowspan="1" colspan="1">35(27.1)</td><td align="left" rowspan="1" colspan="1">9(20.9)</td><td align="left" rowspan="1" colspan="1">0.98</td><td align="left" rowspan="1" colspan="1">0.43 to 2.25</td><td align="left" rowspan="1" colspan="1">0.968</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">TT</td><td align="left" rowspan="1" colspan="1">3(2.3)</td><td align="left" rowspan="1" colspan="1">2(4.8)</td><td align="left" rowspan="1" colspan="1">3.10</td><td align="left" rowspan="1" colspan="1">0.34 to 28.02</td><td align="left" rowspan="1" colspan="1">0.313</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">TT</td><td align="left" rowspan="1" colspan="1">
<bold>6(4.7)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>6(14.0)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>2.94</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.12 to 7.73</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.028</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CT&#x0002b;TT</td><td align="left" rowspan="1" colspan="1">
<bold>25</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>15</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>2.54</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.27 to 5.08</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.008</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.021</bold>
</td><td align="left" rowspan="1" colspan="1">CC&#x0002b;CT vs. TT</td><td align="left" rowspan="1" colspan="1">
<bold>123</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>37</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>2.95</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.14 to 7.63</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.025</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.031</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>IL4:rs2070874</bold>
</td><td align="left" rowspan="1" colspan="1">128</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>IL13:rs180925</bold>
</td><td align="left" rowspan="1" colspan="1">129</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">104(81.3)</td><td align="left" rowspan="1" colspan="1">27(62.8)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">83(64.3)</td><td align="left" rowspan="1" colspan="1">26(60.5)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CT</td><td align="left" rowspan="1" colspan="1">
<bold>21(16.4)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>15(34.9)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>3.09</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.49 to 6.44</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.003</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CT</td><td align="left" rowspan="1" colspan="1">42(32.6)</td><td align="left" rowspan="1" colspan="1">13(30.2)</td><td align="left" rowspan="1" colspan="1">0.71</td><td align="left" rowspan="1" colspan="1">0.33 to 1.52</td><td align="left" rowspan="1" colspan="1">0.380</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">TT</td><td align="left" rowspan="1" colspan="1">3(2.3)</td><td align="left" rowspan="1" colspan="1">1(2.3)</td><td align="left" rowspan="1" colspan="1">2.59</td><td align="left" rowspan="1" colspan="1">0.27 to 24.47</td><td align="left" rowspan="1" colspan="1">0.405</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">TT</td><td align="left" rowspan="1" colspan="1">4(3.1)</td><td align="left" rowspan="1" colspan="1">4(9.3)</td><td align="left" rowspan="1" colspan="1">2.97</td><td align="left" rowspan="1" colspan="1">0.93 to 9.45</td><td align="left" rowspan="1" colspan="1">0.066</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CT&#x0002b;TT</td><td align="left" rowspan="1" colspan="1">
<bold>24</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>16</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>3.05</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.50 to 6.22</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.002</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.010</bold>
</td><td align="left" rowspan="1" colspan="1">CC&#x0002b;CT vs. TT</td><td align="left" rowspan="1" colspan="1">
<bold>125</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>39</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>3.23</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.03 to 10.18</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.045</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.038</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>NFKBIA:rs8904</bold>
</td><td align="left" rowspan="1" colspan="1">127</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">54(42.5)</td><td align="left" rowspan="1" colspan="1">12(27.9)</td><td align="left" rowspan="1" colspan="1">1.00</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CT</td><td align="left" rowspan="1" colspan="1">53(41.7)</td><td align="left" rowspan="1" colspan="1">16(37.2)</td><td align="left" rowspan="1" colspan="1">0.99</td><td align="left" rowspan="1" colspan="1">0.42 to 2.30</td><td align="left" rowspan="1" colspan="1">0.974</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">TT</td><td align="left" rowspan="1" colspan="1">20(15.7)</td><td align="left" rowspan="1" colspan="1">15(34.9)</td><td align="left" rowspan="1" colspan="1">2.00</td><td align="left" rowspan="1" colspan="1">0.84 to 4.79</td><td align="left" rowspan="1" colspan="1">0.119</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CC&#x0002b;CT vs. TT</td><td align="left" rowspan="1" colspan="1">
<bold>107</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>28</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>2.02</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>1.01 to 4.03</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>0.047</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt109"><label/><p>&#x0002a;adjusted for age, gender, pack years, clinical stage, performance status, treatment regimen, radiation type, and radiation dosage.</p></fn></table-wrap-foot></table-wrap><sec id="s2c1"><title>Proinflammatory Genes</title><p>Other significant genetic variants associated with pneumonitis included six SNPs in proinflammatory genes, including <italic>IL1A</italic>, <italic>IL8</italic>, <italic>TNFRSF1B, MIF</italic>, and <italic>NOS3</italic>. Two SNPs in <italic>IL1A</italic> &#x02013; rs1800587 and rs17561&#x02013; are in strong linkage disequilibrium and each resulted in a more than doubling of risk with HRs of 2.90 (95&#x00025; CI:1.34&#x02013;6.25) and 2.51 (95&#x00025; CI:1.19&#x02013;5.27), respectively. The risk associated with IL8:rs4073 was similar at 3.16-fold (95&#x00025; CI:1.54&#x02013;6.48). Under the additive model, TNFRSF1B:rs1061622 resulted in a 2.12-fold increased risk (95&#x00025; CI:1.18&#x02013;3.79). A SNP in the lymphokine gene <italic>MIF</italic> resulted in an even higher HR of 3.96 (95&#x00025; CI:1.04&#x02013;15.12). In contrast, genetic variation in <italic>NOS3</italic> was associated with a 50&#x00025; decrease in pneumonitis risk (HR:0.55, 95&#x00025; CI:0.31&#x02013;0.96). This was the only SNP in our analysis to be significantly associated with a reduction in risk.</p></sec><sec id="s2c2"><title>Anti-inflammatory Genes</title><p>IL4 and IL13 share a common receptor and have many of the same anti-inflammatory functions. In our population, we found that genetic variations in both of these interleukins were associated with increased risks of developing pneumonitis. The two <italic>IL4</italic> SNPs each resulted in increased risk with HRs of 2.54 (95&#x00025; CI:1.27&#x02013;5.08) and 3.05 (95&#x00025; CI:1.50&#x02013;6.22), respectively. <italic>IL13</italic> polymorphisms had a similar effect on pneumonitis risk. Patients with two variant alleles or either rs20541 or rs180925 were approximately 3-times more likely to develop pneumonitis compared to those with wild-type or heterozygous genotypes (HR:2.95, 95&#x00025; CI:1.14&#x02013;7.63 and HR:3.23, 95&#x00025; CI:1.03&#x02013;10.18). The signaling molecule IkappaB-alpha (<italic>NFKBIA</italic>) inhibits the inflammatory response by blocking NFkappaB-mediated transcription of proinflammatory genes. NFKBIA:rs8904 resulted in a 2.02-fold increased pneumonitis risk (95&#x00025; CI:1.01&#x02013;4.03).</p></sec><sec id="s2c3"><title>Joint Analysis of Pneumonitis Risk Alleles</title><p>In combined analysis, the significant SNPs together with an additional borderline significant variant &#x02013; IL4R: rs1801275 (<italic>P</italic>&#x0200a;=&#x0200a;0.053) &#x02013; showed an increase in pneumonitis risk as the number of unfavorable genotypes increased (<xref ref-type="table" rid="pone-0012402-t003">
<bold>Table 3</bold>
</xref>). The increased risk for carrying three unfavorable genotypes was 13.30-fold compared to patients with 0 to 2 risk genotypes (<italic>P</italic>&#x0200a;=&#x0200a;0.013). This risk was dramatically increased for the group of patients with four or more unfavorable genotypes (<italic>P</italic>&#x0003c;0.0001). These high risk individuals also had a shorter duration between start of treatment and development of pneumonitis of only 5.33 months compared to over 12 months for those with 0 to 2 unfavorable genotypes (<xref ref-type="fig" rid="pone-0012402-g001">
<bold>Figure 1B</bold>
</xref>).</p></sec></sec><sec id="s2d"><title>Inflammation-related SNPs and Overall Survival</title><p>The development of toxicity and survival are often related since patients who develop toxicity are those who are responding to treatment. Therefore, we determined if any of the variants identified as toxicity risk factors were also associated with survival over three years. We found that patients with at least one variant allele of IL10:rs1800872 had a 1.74-fold increased risk of esophagitis, but a 40&#x00025; decreased risk of dying when compared to patients with wild-type genotypes (HR:0.62, 95&#x00025; CI:0.40&#x02013;0.97). <xref ref-type="fig" rid="pone-0012402-g002">
<bold>Figure 2A</bold>
</xref> illustrates the time to esophagitis for patients with IL10:rs1800872 genotypes. Although not significant, patients with wild-type genotypes had median time to event of greater than 12 months contrasted with only 1.8 months for those with at least one variant of rs1800872. For survival (<xref ref-type="fig" rid="pone-0012402-g002">
<bold>Figure 2B</bold>
</xref>), there was a non-significant survival advantage of nearly four months for carriers with a median survival time of 16.1 months compared to only 12.4 months for patients with wild-type genotypes.</p><fig id="pone-0012402-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0012402.g002</object-id><label>Figure 2</label><caption><title>Relationship between esophagitis and overall survival.</title><p>(<bold>A</bold>) Kaplan-Meier curves of freedom from grade &#x0003e;2 esophagitis following radiation therapy by IL10:rs1800872 genotypes. Numbers in parentheses are the number of patients with toxicity over the total number of patients; time is median event-free duration in months. (<bold>B</bold>) Kaplan-Meier curves of overall survival following radiation therapy by IL10:rs1800872 genotypes. Numbers in parentheses are the number of patients alive over the total number of patients; time is median survival time in months.</p></caption><graphic xlink:href="pone.0012402.g002"/></fig></sec></sec><sec id="s3"><title>Discussion</title><p>In this study, we systematically analyzed 59 common genetic variations in inflammation-related genes for association with risk of developing acute esophagitis or pneumonitis following radiation treatment in NSCLC patients. Multiple individual SNPs in important pro- and anti-inflammatory genes were identified as modulating risk for both normal tissue toxicities. Furthermore, the cumulative effect of these SNPs was dose-dependent with individuals carrying multiple unfavorable alleles having a corresponding increase in risk.</p><p>Nine genetic variants were identified as significantly associated with esophagitis risk, and of those, six were in proinflammatory genes (<xref ref-type="table" rid="pone-0012402-t002">
<bold>Table 2</bold>
</xref>). We found that rs1800795 in <italic>IL6</italic> resulted in a 2.16-fold increase in esophagitis. This polymorphism is located within the 5&#x02032;-untranslated region of <italic>IL6</italic> and has been functionally studied with conflicting results of the effect on gene expression and response to stimulation <xref rid="pone.0012402-Kiszel1" ref-type="bibr">[18]</xref>, <xref rid="pone.0012402-Terry1" ref-type="bibr">[19]</xref>. However, a recent meta-analysis of over 5,500 patients was not able to demonstrate a relationship between this variant and IL6 serum levels <xref rid="pone.0012402-Huth1" ref-type="bibr">[20]</xref>. Gao et al. demonstrated that IL16:rs11556218 was significantly associated with colorectal and gastric cancer, but did not observe a correlation between IL16 serum levels measured in these patients and rs11556218 <xref rid="pone.0012402-Gao1" ref-type="bibr">[21]</xref>. PTGS2:rs20417 was also associated with increased risk of esophagitis. This promoter variant disrupts a Sp1/Sp3 transcription factor binding site and causes a decrease in transcriptional activity in lung fibroblast cells <xref rid="pone.0012402-Hill1" ref-type="bibr">[22]</xref>, <xref rid="pone.0012402-Papafili1" ref-type="bibr">[23]</xref>. Decreased expression of COX2 would suggest a decrease in inflammation signaling. However, this same variant, while altering the Sp1/Sp3 site, also introduces a binding site for another transcription factor, Egr-1, although the consequences are unknown <xref rid="pone.0012402-Hill1" ref-type="bibr">[22]</xref>. The other two significant variants (rs5275 and rs689470) are located in the 3&#x02032;-UTR and regulate <italic>PSTGS2</italic> mRNA levels. Our results suggest that these SNPs are linked with an increase in pro-inflammatory activity leading to esophagitis. Further functional analysis is warranted to understand the underlying mechanisms <xref rid="pone.0012402-Dixon1" ref-type="bibr">[24]</xref>.</p><p>For anti-inflammatory molecules and esophagitis risk, Khurana Hershey et al. demonstrated that IL4R:rs1801275 resulted in enhanced IL4 signaling and the induction of high levels of the IgE receptor CD23 <xref rid="pone.0012402-Hershey1" ref-type="bibr">[25]</xref>. IL10:rs1800872 and IL10RA:rs3135932 have been shown to decrease IL10 signaling by decreasing serum levels and altering IL10-IL10RA interactions, respectively <xref rid="pone.0012402-Crawley1" ref-type="bibr">[26]</xref>, <xref rid="pone.0012402-Gasche1" ref-type="bibr">[27]</xref>. The reported functions of these three SNPs would be in agreement with our findings of an increased risk of esophagitis by decreasing the anti-inflammatory response.</p><p>Twelve common polymorphisms were found to be significantly associated with risk of pneumonitis. The two <italic>IL1A</italic> variants are in linkage disequilibrium and were found to increase risk by nearly 3-fold. IL1A:rs1800587 has been shown to contribute to an increase in IL1-&#x003b1; promoter activity, mRNA levels and protein levels <xref rid="pone.0012402-Dominici1" ref-type="bibr">[28]</xref>. IL1A:rs17561 is a non-synonymous SNP and increases processing of the IL1-&#x003b1; precursor resulting in an increase in the levels of active IL1-&#x003b1; <xref rid="pone.0012402-Kawaguchi1" ref-type="bibr">[29]</xref>. The variant of IL8:rs4073, which was found to increase pneumonitis risk 3-fold, has been associated with increased secretion of the proinflammatory cytokine IL8 <xref rid="pone.0012402-Hull1" ref-type="bibr">[30]</xref>. IL4 and IL13 work together to regulate the inflammatory response. Four genetic variants in these two genes were associated with &#x0223c;3-fold increased risk of pneumonitis. Studies have demonstrated increased IgE production for IL4:rs2070874 and rs2243250 <xref rid="pone.0012402-Kabesch1" ref-type="bibr">[31]</xref> and increased IL13 activity for IL13:rs20541 and rs180925 <xref rid="pone.0012402-Vladich1" ref-type="bibr">[32]</xref>, <xref rid="pone.0012402-Cameron1" ref-type="bibr">[33]</xref>.</p><p>Genetic variation in <italic>TNF</italic> and the receptor <italic>TNFRSF1B</italic> were also associated with increased risk of pneumonitis. TNF-&#x003b1; signaling is an important modulator of the inflammatory response. The TNF:rs1799724 variant is located within the promoter region of the gene and thought to influence gene expression by creating an OCT-1 transcription factor binding site <xref rid="pone.0012402-Hohjoh1" ref-type="bibr">[34]</xref>. The effect of this differential binding on TNF-&#x003b1; signaling is not clear. Some studies have shown an increase in TNF-&#x003b1; production <xref rid="pone.0012402-Higuchi1" ref-type="bibr">[35]</xref>, <xref rid="pone.0012402-Lv1" ref-type="bibr">[36]</xref>, <xref rid="pone.0012402-Soga1" ref-type="bibr">[37]</xref>, while others have shown the opposite effect <xref rid="pone.0012402-Puthothu1" ref-type="bibr">[38]</xref>, <xref rid="pone.0012402-Sato1" ref-type="bibr">[39]</xref>, <xref rid="pone.0012402-vanHeel1" ref-type="bibr">[40]</xref>. For TNFRSF1B, the non-synonymous variant Met196Arg (rs1061622) does not alter TNF-&#x003b1; binding affinity, but results in intensified TNF-&#x003b1; signaling <xref rid="pone.0012402-Morita1" ref-type="bibr">[41]</xref> and decreased NF-kB signaling <xref rid="pone.0012402-Till1" ref-type="bibr">[42]</xref>.</p><p>Only one genetic variant was found to confer a protective effect following radiotherapy. This variant, rs1799983, in <italic>NOS3</italic> was associated with a 70&#x00025; reduction in risk of pneumonitis. Functional studies have demonstrated that this variant results in production of a variant allozyme with reduced enzyme activity <xref rid="pone.0012402-Wang2" ref-type="bibr">[43]</xref> resulting in a reduction in nitric oxide production <xref rid="pone.0012402-Veldman1" ref-type="bibr">[44]</xref>. These observations support our findings of decreased pneumonitis due to decreased inflammatory signaling.</p><p>In all, the functional consequences of the variants identified as strongly associated with increased risk of normal tissue toxicity following radiation exposure suggest a high biological plausibility for our findings. However, little to no information is known about how these variants specifically alter pneumonitis and esophagitis risk. The inflammatory response is complex and many prototypic &#x0201c;proinflammatory&#x0201d; molecules have anti-inflammatory attributes under specific conditions, and vice versa. Further studies are warranted to elucidate the specific function of these SNPs in target tissues following exposure to radiation.</p><p>Interestingly, we observed several variants with a trend towards a relationship between toxicity and overall survival, and only one SNP was identified as being associated with both. This result suggests that these patients who are developing acute normal tissue toxicity are responding well to therapy with longer survival times. Unfortunately, these side effects are dose limiting and often result in cessation of treatment. It may be that these select patients would receive the most benefit from the inclusion of radioprotective agents such as amifostine and glutamine in their treatment regimen. Both work by decreasing the levels of reactive oxygen species in the exposed normal tissue and, thus, potentially avoiding the development of inflammation. It would be of interest to test the significant SNPs identified in this study within the framework of these agents.</p><p>Our study has several advantages, including the patient population with availability of comprehensive clinical and epidemiological information. To our knowledge, no study has systematically investigated the effect of genetic variations within inflammation-related genes and risk of normal tissue toxicity due to radiation therapy. This pathway-based approach allowed us to comprehensively elucidate the cumulative effects of multiple adverse alleles on toxicity risk. Since a patient's genome can contain several of these risk associated genetic variants in both proinflammatory and anti-inflammatory pathways, this approach is much more powerful in detecting the effect of these SNPs on a patient's risk of developing esophagitis or pneumonitis. The variants included in this study were candidate SNPs based on known or predicted effects on gene function. A candidate-gene approach has the advantage of being anchored by known biological plausibility, but there is a possibility that this study has missed additional risk alleles or detected a variant in linkage disequilibrium with the true causative SNP. In addition, we were not able to include additional variables that may also impact toxicity, including radiation field size, dose to organ at risk (esophagus and lung), treatment volume, and tumor location.</p><p>In conclusion, we identified several biologically plausible associations between genetic variants in important inflammation-related genes and risk of developing esophagitis and pneumonitis. We also demonstrated a dose-effect of inflammation SNPs as evidenced by the dramatic increases in risk with increases in number of unfavorable genotypes. Furthermore, we identified one variant in IL10 that is associated with increased risk of esophagitis, but a decreased risk of dying. Since radiotherapy is a mainstay of lung cancer treatment, having the ability to screen patients prior to initiation of treatment would potentially minimize these acute toxicity events while allowing for higher doses of radiation for those who are not at increased risk in order to improve local control. With validation, these results, together with clinical and dosimetric predictors, could serve to increase the overall benefit of radiation therapy in NSCLC patients.</p></sec><sec sec-type="methods" id="s4"><title>Methods</title><sec id="s4a"><title>Ethics Statement</title><p>Participants gave written informed consent and the study was approved by The University of Texas MD Anderson Cancer Center's Institutional Review Board.</p></sec><sec id="s4b"><title>Patient Population</title><p>The study included non-Hispanic Caucasian subjects who were newly diagnosed, histologically confirmed stage IIIA or IIIB without a malignant effusion (dry) NSCLC patients receiving definitive thoracic radiation or chemoradiation therapy at The University of Texas MD Anderson Cancer Center. All of the patients were enrolled in an ongoing epidemiology lung cancer study between 1995 and 2007.</p></sec><sec id="s4c"><title>Epidemiological and Clinical Data Collection</title><p>Epidemiologic data were collected during an in-person interview using a structured questionnaire to determine demographic characteristics, medical history, and smoking history. Clinical and follow-up information was abstracted from medical records. Pre-treatment performance status was determined based on the Eastern Cooperative Oncology Group scale. Radiation-induced esophagitis was characterized by documentation of new-onset pain on swallowing occurring during treatment. Pneumonitis was detected by roentgenographic or CT scan abnormalities and often associated with nonproductive cough and/or fever. Severity of pneumonitis or esophagitis was scored by the physician according to National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0) guidelines <xref rid="pone.0012402-Trotti1" ref-type="bibr">[45]</xref>. For this study, an event was considered the occurrence of grade &#x02265;2 toxicity.</p></sec><sec id="s4d"><title>SNP Selection and Genotyping</title><p>Blood was drawn from each participant following the in-person interview. These samples were used to extract genomic DNA from peripheral blood lymphocytes using the Human Whole Blood Genomic DNA Extraction Kit (Qiagen, Valencia, CA). A total of 59 candidate SNPs (<xref ref-type="table" rid="pone-0012402-t005">
<bold>Table 5</bold>
</xref>) were selected from 37 known inflammation-related genes as previously described <xref rid="pone.0012402-Engels1" ref-type="bibr">[46]</xref>. Briefly, candidate SNPs were selected if they had a minor allele frequency greater than 5&#x00025; and were located in a putative functional region of the gene (promoter, untranslated regions (UTR) or exons) or had previously been reported as associated with cancer or an inflammatory disorder. Genotyping was performed using the SNPlex assay following manufacturer's instructions (Applied Biosystems, Foster City, CA) with analysis on an Applied Biosystems 3730 DNA Analyzer. SNP genotypes were called using the GeneMapper software (Applied Biosystems). Three SNPs: IL8RA:rs2234671, LTA:rs2229092 and IL4R:rs1805011 were removed because of excessive missing genotypes (&#x0003e;20&#x00025;). All genotyping was completed blinded with regard to toxicity status.</p><table-wrap id="pone-0012402-t005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0012402.t005</object-id><label>Table5</label><caption><title>Inflammation single nucleotide polymorphism characteristics.</title></caption><alternatives><graphic id="pone-0012402-t005-5" xlink:href="pone.0012402.t005"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">dbSNP ID</td><td align="left" rowspan="1" colspan="1">Alleles</td><td align="left" rowspan="1" colspan="1">Gene Symbol</td><td align="left" rowspan="1" colspan="1">Gene Name</td><td align="left" rowspan="1" colspan="1">SNP Location<xref ref-type="table-fn" rid="nt110">&#x0002a;</xref>
</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">rs1800872</td><td align="left" rowspan="1" colspan="1">C/A</td><td align="left" rowspan="1" colspan="1">IL10</td><td align="left" rowspan="1" colspan="1">interleukin 10</td><td align="left" rowspan="1" colspan="1">5'-FR</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1800896</td><td align="left" rowspan="1" colspan="1">G/A</td><td align="left" rowspan="1" colspan="1">IL10</td><td align="left" rowspan="1" colspan="1">interleukin 10</td><td align="left" rowspan="1" colspan="1">5'-FR</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1900871</td><td align="left" rowspan="1" colspan="1">A/C</td><td align="left" rowspan="1" colspan="1">IL10</td><td align="left" rowspan="1" colspan="1">interleukin 10</td><td align="left" rowspan="1" colspan="1">5'-FR</td></tr><tr><td align="left" rowspan="1" colspan="1">rs3135932</td><td align="left" rowspan="1" colspan="1">A/G</td><td align="left" rowspan="1" colspan="1">IL10RA</td><td align="left" rowspan="1" colspan="1">interleukin 10 receptor, alpha</td><td align="left" rowspan="1" colspan="1">Ser159Gly</td></tr><tr><td align="left" rowspan="1" colspan="1">rs2834167</td><td align="left" rowspan="1" colspan="1">A/G</td><td align="left" rowspan="1" colspan="1">IL10RB</td><td align="left" rowspan="1" colspan="1">interleukin 10 receptor, beta</td><td align="left" rowspan="1" colspan="1">Lys47Glu</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1800925</td><td align="left" rowspan="1" colspan="1">C/T</td><td align="left" rowspan="1" colspan="1">IL13</td><td align="left" rowspan="1" colspan="1">interleukin 13</td><td align="left" rowspan="1" colspan="1">5'-FR</td></tr><tr><td align="left" rowspan="1" colspan="1">rs20541</td><td align="left" rowspan="1" colspan="1">C/T</td><td align="left" rowspan="1" colspan="1">IL13</td><td align="left" rowspan="1" colspan="1">interleukin 13</td><td align="left" rowspan="1" colspan="1">Arg130Gln</td></tr><tr><td align="left" rowspan="1" colspan="1">rs2070874</td><td align="left" rowspan="1" colspan="1">C/T</td><td align="left" rowspan="1" colspan="1">IL4</td><td align="left" rowspan="1" colspan="1">interleukin 4</td><td align="left" rowspan="1" colspan="1">5'-UTR</td></tr><tr><td align="left" rowspan="1" colspan="1">rs2243250</td><td align="left" rowspan="1" colspan="1">C/T</td><td align="left" rowspan="1" colspan="1">IL4</td><td align="left" rowspan="1" colspan="1">interleukin 4</td><td align="left" rowspan="1" colspan="1">5'-FR</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1801275</td><td align="left" rowspan="1" colspan="1">A/G</td><td align="left" rowspan="1" colspan="1">IL4R</td><td align="left" rowspan="1" colspan="1">interleukin 4 receptor</td><td align="left" rowspan="1" colspan="1">Gln576Arg</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1805010</td><td align="left" rowspan="1" colspan="1">A/G</td><td align="left" rowspan="1" colspan="1">IL4R</td><td align="left" rowspan="1" colspan="1">interleukin 4 receptor</td><td align="left" rowspan="1" colspan="1">Ile75Val</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1805011</td><td align="left" rowspan="1" colspan="1">A/C</td><td align="left" rowspan="1" colspan="1">IL4R</td><td align="left" rowspan="1" colspan="1">interleukin 4 receptor</td><td align="left" rowspan="1" colspan="1">Glu400Ala</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1805015</td><td align="left" rowspan="1" colspan="1">T/C</td><td align="left" rowspan="1" colspan="1">IL4R</td><td align="left" rowspan="1" colspan="1">interleukin 4 receptor</td><td align="left" rowspan="1" colspan="1">Ser503Pro</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1805016</td><td align="left" rowspan="1" colspan="1">T/G</td><td align="left" rowspan="1" colspan="1">IL4R</td><td align="left" rowspan="1" colspan="1">interleukin 4 receptor</td><td align="left" rowspan="1" colspan="1">Ser752Ala</td></tr><tr><td align="left" rowspan="1" colspan="1">rs2069812</td><td align="left" rowspan="1" colspan="1">C/T</td><td align="left" rowspan="1" colspan="1">IL5</td><td align="left" rowspan="1" colspan="1">interleukin 5 receptor</td><td align="left" rowspan="1" colspan="1">5'-FR</td></tr><tr><td align="left" rowspan="1" colspan="1">rs2233409</td><td align="left" rowspan="1" colspan="1">C/T</td><td align="left" rowspan="1" colspan="1">NFKBIA</td><td align="left" rowspan="1" colspan="1">IkB alpha</td><td align="left" rowspan="1" colspan="1">5'-FR</td></tr><tr><td align="left" rowspan="1" colspan="1">rs8904</td><td align="left" rowspan="1" colspan="1">C/T</td><td align="left" rowspan="1" colspan="1">NFKBIA</td><td align="left" rowspan="1" colspan="1">IkB alpha</td><td align="left" rowspan="1" colspan="1">3'-UTR</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1800206</td><td align="left" rowspan="1" colspan="1">C/G</td><td align="left" rowspan="1" colspan="1">PPARA</td><td align="left" rowspan="1" colspan="1">peroxisome proliferator-activated receptor alpha</td><td align="left" rowspan="1" colspan="1">Leu162Val</td></tr><tr><td align="left" rowspan="1" colspan="1">rs2016520</td><td align="left" rowspan="1" colspan="1">A/G</td><td align="left" rowspan="1" colspan="1">PPARD</td><td align="left" rowspan="1" colspan="1">peroxisome proliferator-activated receptor delta</td><td align="left" rowspan="1" colspan="1">5'-UTR</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1801282</td><td align="left" rowspan="1" colspan="1">C/G</td><td align="left" rowspan="1" colspan="1">PPARG</td><td align="left" rowspan="1" colspan="1">peroxisome proliferator-activated receptor gamma</td><td align="left" rowspan="1" colspan="1">Pro12Ala</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1024611</td><td align="left" rowspan="1" colspan="1">T/C</td><td align="left" rowspan="1" colspan="1">CCL2</td><td align="left" rowspan="1" colspan="1">chemokine (C-C motif) ligand 2</td><td align="left" rowspan="1" colspan="1">5'-FR</td></tr><tr><td align="left" rowspan="1" colspan="1">rs2069614</td><td align="left" rowspan="1" colspan="1">C/T</td><td align="left" rowspan="1" colspan="1">CSF2</td><td align="left" rowspan="1" colspan="1">colony stimulating factor 2 (granulocyte-macrophage)</td><td align="left" rowspan="1" colspan="1">5'-FR</td></tr><tr><td align="left" rowspan="1" colspan="1">rs25882</td><td align="left" rowspan="1" colspan="1">T/C</td><td align="left" rowspan="1" colspan="1">CSF2</td><td align="left" rowspan="1" colspan="1">colony stimulating factor 2 (granulocyte-macrophage)</td><td align="left" rowspan="1" colspan="1">Ile117Thr</td></tr><tr><td align="left" rowspan="1" colspan="1">rs2257167</td><td align="left" rowspan="1" colspan="1">G/C</td><td align="left" rowspan="1" colspan="1">IFNAR1</td><td align="left" rowspan="1" colspan="1">interferon (alpha, beta and omega) receptor 1</td><td align="left" rowspan="1" colspan="1">Val168Leu</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1051393</td><td align="left" rowspan="1" colspan="1">T/G</td><td align="left" rowspan="1" colspan="1">IFNAR2</td><td align="left" rowspan="1" colspan="1">interferon (alpha, beta and omega) receptor 2</td><td align="left" rowspan="1" colspan="1">Phe10Val</td></tr><tr><td align="left" rowspan="1" colspan="1">rs2069705</td><td align="left" rowspan="1" colspan="1">T/C</td><td align="left" rowspan="1" colspan="1">IFNG</td><td align="left" rowspan="1" colspan="1">interferon, gamma</td><td align="left" rowspan="1" colspan="1">5'-FR</td></tr><tr><td align="left" rowspan="1" colspan="1">rs2430561</td><td align="left" rowspan="1" colspan="1">A/T</td><td align="left" rowspan="1" colspan="1">IFNG</td><td align="left" rowspan="1" colspan="1">interferon, gamma</td><td align="left" rowspan="1" colspan="1">intron</td></tr><tr><td align="left" rowspan="1" colspan="1">rs3212227</td><td align="left" rowspan="1" colspan="1">A/C</td><td align="left" rowspan="1" colspan="1">IL12B</td><td align="left" rowspan="1" colspan="1">interleukin 12B</td><td align="left" rowspan="1" colspan="1">3'-UTR</td></tr><tr><td align="left" rowspan="1" colspan="1">rs375947</td><td align="left" rowspan="1" colspan="1">A/G</td><td align="left" rowspan="1" colspan="1">IL12RB</td><td align="left" rowspan="1" colspan="1">interleukin 12 receptor, beta 1</td><td align="left" rowspan="1" colspan="1">Met365Thr</td></tr><tr><td align="left" rowspan="1" colspan="1">rs11556218</td><td align="left" rowspan="1" colspan="1">T/G</td><td align="left" rowspan="1" colspan="1">IL16</td><td align="left" rowspan="1" colspan="1">interleukin 16</td><td align="left" rowspan="1" colspan="1">Asn446Lys</td></tr><tr><td align="left" rowspan="1" colspan="1">rs4778889</td><td align="left" rowspan="1" colspan="1">T/C</td><td align="left" rowspan="1" colspan="1">IL16</td><td align="left" rowspan="1" colspan="1">interleukin 16</td><td align="left" rowspan="1" colspan="1">5'-FR</td></tr><tr><td align="left" rowspan="1" colspan="1">rs17561</td><td align="left" rowspan="1" colspan="1">G/T</td><td align="left" rowspan="1" colspan="1">IL1A</td><td align="left" rowspan="1" colspan="1">interleukin 1, alpha</td><td align="left" rowspan="1" colspan="1">Ala114Ser</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1800587</td><td align="left" rowspan="1" colspan="1">C/T</td><td align="left" rowspan="1" colspan="1">IL1A</td><td align="left" rowspan="1" colspan="1">interleukin 1, alpha</td><td align="left" rowspan="1" colspan="1">5'-FR</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1143627</td><td align="left" rowspan="1" colspan="1">T/C</td><td align="left" rowspan="1" colspan="1">IL1B</td><td align="left" rowspan="1" colspan="1">interleukin 1, beta</td><td align="left" rowspan="1" colspan="1">5'-FR</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1143634</td><td align="left" rowspan="1" colspan="1">C/T</td><td align="left" rowspan="1" colspan="1">IL1B</td><td align="left" rowspan="1" colspan="1">interleukin 1, beta</td><td align="left" rowspan="1" colspan="1">Phe105Phe</td></tr><tr><td align="left" rowspan="1" colspan="1">rs16944</td><td align="left" rowspan="1" colspan="1">C/T</td><td align="left" rowspan="1" colspan="1">IL1B</td><td align="left" rowspan="1" colspan="1">interleukin 1, beta</td><td align="left" rowspan="1" colspan="1">5'-FR</td></tr><tr><td align="left" rowspan="1" colspan="1">rs2228139</td><td align="left" rowspan="1" colspan="1">C/G</td><td align="left" rowspan="1" colspan="1">IL1R1</td><td align="left" rowspan="1" colspan="1">interleukin 1 receptor, type I</td><td align="left" rowspan="1" colspan="1">Ala124Gly</td></tr><tr><td align="left" rowspan="1" colspan="1">rs2069762</td><td align="left" rowspan="1" colspan="1">T/G</td><td align="left" rowspan="1" colspan="1">IL2</td><td align="left" rowspan="1" colspan="1">interleukin 2</td><td align="left" rowspan="1" colspan="1">5'-FR</td></tr><tr><td align="left" rowspan="1" colspan="1">rs228942</td><td align="left" rowspan="1" colspan="1">C/A</td><td align="left" rowspan="1" colspan="1">IL2RB</td><td align="left" rowspan="1" colspan="1">interleukin 2 receptor, beta</td><td align="left" rowspan="1" colspan="1">Asp391Glu</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1800795</td><td align="left" rowspan="1" colspan="1">C/G</td><td align="left" rowspan="1" colspan="1">IL6</td><td align="left" rowspan="1" colspan="1">interleukin 6 (interferon, beta 2)</td><td align="left" rowspan="1" colspan="1">5'-FR</td></tr><tr><td align="left" rowspan="1" colspan="1">rs2228145</td><td align="left" rowspan="1" colspan="1">A/C</td><td align="left" rowspan="1" colspan="1">IL6R</td><td align="left" rowspan="1" colspan="1">interleukin 6 receptor</td><td align="left" rowspan="1" colspan="1">Asp358Ala</td></tr><tr><td align="left" rowspan="1" colspan="1">rs4073</td><td align="left" rowspan="1" colspan="1">T/A</td><td align="left" rowspan="1" colspan="1">IL8</td><td align="left" rowspan="1" colspan="1">interleukin 8</td><td align="left" rowspan="1" colspan="1">5'-FR</td></tr><tr><td align="left" rowspan="1" colspan="1">rs2234671</td><td align="left" rowspan="1" colspan="1">G/C</td><td align="left" rowspan="1" colspan="1">IL8RA</td><td align="left" rowspan="1" colspan="1">interleukin 8 receptor, alpha</td><td align="left" rowspan="1" colspan="1">Ser276Thr</td></tr><tr><td align="left" rowspan="1" colspan="1">rs2229092</td><td align="left" rowspan="1" colspan="1">A/C</td><td align="left" rowspan="1" colspan="1">LTA</td><td align="left" rowspan="1" colspan="1">lymphotoxin alpha</td><td align="left" rowspan="1" colspan="1">His51Pro</td></tr><tr><td align="left" rowspan="1" colspan="1">rs2229094</td><td align="left" rowspan="1" colspan="1">T/C</td><td align="left" rowspan="1" colspan="1">LTA</td><td align="left" rowspan="1" colspan="1">lymphotoxin alpha</td><td align="left" rowspan="1" colspan="1">Arg13Cys</td></tr><tr><td align="left" rowspan="1" colspan="1">rs755622</td><td align="left" rowspan="1" colspan="1">C/G</td><td align="left" rowspan="1" colspan="1">MIF</td><td align="left" rowspan="1" colspan="1">macrophage migration inhibitory factor</td><td align="left" rowspan="1" colspan="1">5'-FR</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1799724</td><td align="left" rowspan="1" colspan="1">C/T</td><td align="left" rowspan="1" colspan="1">TNF</td><td align="left" rowspan="1" colspan="1">tumor necrosis factor</td><td align="left" rowspan="1" colspan="1">5'-FR</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1799964</td><td align="left" rowspan="1" colspan="1">T/C</td><td align="left" rowspan="1" colspan="1">TNF</td><td align="left" rowspan="1" colspan="1">tumor necrosis factor</td><td align="left" rowspan="1" colspan="1">5'-FR</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1800629</td><td align="left" rowspan="1" colspan="1">G/A</td><td align="left" rowspan="1" colspan="1">TNF</td><td align="left" rowspan="1" colspan="1">tumor necrosis factor</td><td align="left" rowspan="1" colspan="1">5'-FR</td></tr><tr><td align="left" rowspan="1" colspan="1">rs361525</td><td align="left" rowspan="1" colspan="1">G/A</td><td align="left" rowspan="1" colspan="1">TNF</td><td align="left" rowspan="1" colspan="1">tumor necrosis factor</td><td align="left" rowspan="1" colspan="1">5'-FR</td></tr><tr><td align="left" rowspan="1" colspan="1">rs4149570</td><td align="left" rowspan="1" colspan="1">G/T</td><td align="left" rowspan="1" colspan="1">TNFRSF1A</td><td align="left" rowspan="1" colspan="1">tumor necrosis factor receptor superfamily, member 1A</td><td align="left" rowspan="1" colspan="1">5'-FR</td></tr><tr><td align="left" rowspan="1" colspan="1">rs4149584</td><td align="left" rowspan="1" colspan="1">G/A</td><td align="left" rowspan="1" colspan="1">TNFRSF1A</td><td align="left" rowspan="1" colspan="1">tumor necrosis factor receptor superfamily, member 1A</td><td align="left" rowspan="1" colspan="1">Arg121Gln</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1061622</td><td align="left" rowspan="1" colspan="1">T/G</td><td align="left" rowspan="1" colspan="1">TNFRSF1B</td><td align="left" rowspan="1" colspan="1">tumor necrosis factor receptor superfamily, member 1B</td><td align="left" rowspan="1" colspan="1">Met196Arg</td></tr><tr><td align="left" rowspan="1" colspan="1">rs5746026</td><td align="left" rowspan="1" colspan="1">G/A</td><td align="left" rowspan="1" colspan="1">TNFRSF1B</td><td align="left" rowspan="1" colspan="1">tumor necrosis factor receptor superfamily, member 1B</td><td align="left" rowspan="1" colspan="1">Glu232Lys</td></tr><tr><td align="left" rowspan="1" colspan="1">rs2297518</td><td align="left" rowspan="1" colspan="1">G/A</td><td align="left" rowspan="1" colspan="1">NOS2</td><td align="left" rowspan="1" colspan="1">nitric oxide synthase 2, inducible</td><td align="left" rowspan="1" colspan="1">Leu608Ser</td></tr><tr><td align="left" rowspan="1" colspan="1">rs1799983</td><td align="left" rowspan="1" colspan="1">G/T</td><td align="left" rowspan="1" colspan="1">NOS3</td><td align="left" rowspan="1" colspan="1">nitric oxide synthase 3 (endothelial cell)</td><td align="left" rowspan="1" colspan="1">Glu298Asp</td></tr><tr><td align="left" rowspan="1" colspan="1">rs20417</td><td align="left" rowspan="1" colspan="1">G/C</td><td align="left" rowspan="1" colspan="1">PTGS2</td><td align="left" rowspan="1" colspan="1">prostaglandin-endoperoxide synthase 2</td><td align="left" rowspan="1" colspan="1">5'-FR</td></tr><tr><td align="left" rowspan="1" colspan="1">rs5275</td><td align="left" rowspan="1" colspan="1">T/C</td><td align="left" rowspan="1" colspan="1">PTGS2</td><td align="left" rowspan="1" colspan="1">prostaglandin-endoperoxide synthase 2</td><td align="left" rowspan="1" colspan="1">3'-UTR</td></tr><tr><td align="left" rowspan="1" colspan="1">rs689470</td><td align="left" rowspan="1" colspan="1">C/T</td><td align="left" rowspan="1" colspan="1">PTGS2</td><td align="left" rowspan="1" colspan="1">prostaglandin-endoperoxide synthase 2</td><td align="left" rowspan="1" colspan="1">3'-UTR</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt110"><label/><p>&#x0002a;FR: flanking region, UTR: untranslated region.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s4e"><title>Statistical Analysis</title><p>Time to event (grade &#x02265;2 pneumonitis or esophagitis) was based on the duration from start of radiation treatment to occurrence of toxicity. Three-year survival was also defined as the time from start of radiation treatment to the date of death or the date of last follow-up during the three year period. Hazard ratios (HRs) and 95&#x00025; confidence intervals (95&#x00025; CIs) for each individual SNP and endpoint combination were estimated by fitting the Cox proportional hazard model while adjusting for age, gender, clinical stage, pack years of smoking, pre-treatment performance status, treatment regimen (radiotherapy or chemoradiotherapy), radiation type, and radiation dosage. Kaplan-Meier curves and log-rank tests were used to assess differences in time to event and overall survival rates. Combined effects of unfavorable genotypes were based on the main effect analysis of individual SNPs and included those with significant (<italic>P</italic>&#x0003c;0.05) and borderline significant (<italic>P</italic>&#x0003c;0.10) associations. STATA software (version 10, STATA Corp., College Station, TX) was used for statistical analyses. Q-values were calculated to control for multiple comparisons based on an FDR value of 10&#x00025; <xref rid="pone.0012402-Storey1" ref-type="bibr">[47]</xref>.</p></sec></sec></body><back><fn-group><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This work was supported by National Cancer Institute grants R01 CA111646, P50 CA070907, R01 CA127219, and R01 CA55769. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group><ref-list><title>References</title><ref id="pone.0012402-Jemal1"><label>1</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Siegel</surname><given-names>R</given-names></name><name><surname>Ward</surname><given-names>E</given-names></name><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>Cancer statistics, 2008.</article-title>
<source>CA Cancer J Clin</source>
<volume>58</volume>
<fpage>71</fpage>
<lpage>96</lpage>
<pub-id pub-id-type="pmid">18287387</pub-id></element-citation></ref><ref id="pone.0012402-Spira1"><label>2</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Spira</surname><given-names>A</given-names></name><name><surname>Ettinger</surname><given-names>DS</given-names></name></person-group>
<year>2004</year>
<article-title>Multidisciplinary management of lung cancer.</article-title>
<source>N Engl J Med</source>
<volume>350</volume>
<fpage>379</fpage>
<lpage>392</lpage>
<pub-id pub-id-type="pmid">14736930</pub-id></element-citation></ref><ref id="pone.0012402-Greenlee1"><label>3</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Greenlee</surname><given-names>RT</given-names></name><name><surname>Murray</surname><given-names>T</given-names></name><name><surname>Bolden</surname><given-names>S</given-names></name><name><surname>Wingo</surname><given-names>PA</given-names></name></person-group>
<year>2000</year>
<article-title>Cancer statistics, 2000.</article-title>
<source>CA Cancer J Clin</source>
<volume>50</volume>
<fpage>7</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="pmid">10735013</pub-id></element-citation></ref><ref id="pone.0012402-Rubin1"><label>4</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rubin</surname><given-names>P</given-names></name><name><surname>Johnston</surname><given-names>CJ</given-names></name><name><surname>Williams</surname><given-names>JP</given-names></name><name><surname>McDonald</surname><given-names>S</given-names></name><name><surname>Finkelstein</surname><given-names>JN</given-names></name></person-group>
<year>1995</year>
<article-title>A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis.</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<volume>33</volume>
<fpage>99</fpage>
<lpage>109</lpage>
<pub-id pub-id-type="pmid">7642437</pub-id></element-citation></ref><ref id="pone.0012402-Robnett1"><label>5</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Robnett</surname><given-names>TJ</given-names></name><name><surname>Machtay</surname><given-names>M</given-names></name><name><surname>Vines</surname><given-names>EF</given-names></name><name><surname>McKenna</surname><given-names>MG</given-names></name><name><surname>Algazy</surname><given-names>KM</given-names></name><etal/></person-group>
<year>2000</year>
<article-title>Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer.</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<volume>48</volume>
<fpage>89</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="pmid">10924976</pub-id></element-citation></ref><ref id="pone.0012402-Rose1"><label>6</label><element-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Rose</surname><given-names>J</given-names></name><name><surname>Rodrigues</surname><given-names>G</given-names></name><name><surname>Yaremko</surname><given-names>B</given-names></name><name><surname>Lock</surname><given-names>M</given-names></name><name><surname>D'Souza</surname><given-names>D</given-names></name></person-group>
<year>2008</year>
<article-title>Systematic review of dose-volume parameters in the prediction of esophagitis in thoracic radiotherapy.</article-title>
<source>Radiother Oncol</source>
</element-citation></ref><ref id="pone.0012402-Singh1"><label>7</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singh</surname><given-names>AK</given-names></name><name><surname>Lockett</surname><given-names>MA</given-names></name><name><surname>Bradley</surname><given-names>JD</given-names></name></person-group>
<year>2003</year>
<article-title>Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy.</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<volume>55</volume>
<fpage>337</fpage>
<lpage>341</lpage>
<pub-id pub-id-type="pmid">12527046</pub-id></element-citation></ref><ref id="pone.0012402-Tucker1"><label>8</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tucker</surname><given-names>SL</given-names></name><name><surname>Liu</surname><given-names>HH</given-names></name><name><surname>Liao</surname><given-names>Z</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>Analysis of radiation pneumonitis risk using a generalized Lyman model.</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<volume>72</volume>
<fpage>568</fpage>
<lpage>574</lpage>
<pub-id pub-id-type="pmid">18793959</pub-id></element-citation></ref><ref id="pone.0012402-Wang1"><label>9</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Liao</surname><given-names>Z</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>HH</given-names></name><name><surname>Tucker</surname><given-names>SL</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT).</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<volume>66</volume>
<fpage>1399</fpage>
<lpage>1407</lpage>
<pub-id pub-id-type="pmid">16997503</pub-id></element-citation></ref><ref id="pone.0012402-Dinarello1"><label>10</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dinarello</surname><given-names>CA</given-names></name></person-group>
<year>2000</year>
<article-title>Proinflammatory cytokines.</article-title>
<source>Chest</source>
<volume>118</volume>
<fpage>503</fpage>
<lpage>508</lpage>
<pub-id pub-id-type="pmid">10936147</pub-id></element-citation></ref><ref id="pone.0012402-Opal1"><label>11</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Opal</surname><given-names>SM</given-names></name><name><surname>DePalo</surname><given-names>VA</given-names></name></person-group>
<year>2000</year>
<article-title>Anti-inflammatory cytokines.</article-title>
<source>Chest</source>
<volume>117</volume>
<fpage>1162</fpage>
<lpage>1172</lpage>
<pub-id pub-id-type="pmid">10767254</pub-id></element-citation></ref><ref id="pone.0012402-Barnett1"><label>12</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barnett</surname><given-names>GC</given-names></name><name><surname>West</surname><given-names>CM</given-names></name><name><surname>Dunning</surname><given-names>AM</given-names></name><name><surname>Elliott</surname><given-names>RM</given-names></name><name><surname>Coles</surname><given-names>CE</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype.</article-title>
<source>Nat Rev Cancer</source>
<volume>9</volume>
<fpage>134</fpage>
<lpage>142</lpage>
<pub-id pub-id-type="pmid">19148183</pub-id></element-citation></ref><ref id="pone.0012402-Andreassen1"><label>13</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Andreassen</surname><given-names>CN</given-names></name><name><surname>Alsner</surname><given-names>J</given-names></name><name><surname>Overgaard</surname><given-names>M</given-names></name><name><surname>Overgaard</surname><given-names>J</given-names></name></person-group>
<year>2003</year>
<article-title>Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes.</article-title>
<source>Radiother Oncol</source>
<volume>69</volume>
<fpage>127</fpage>
<lpage>135</lpage>
<pub-id pub-id-type="pmid">14643949</pub-id></element-citation></ref><ref id="pone.0012402-Andreassen2"><label>14</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Andreassen</surname><given-names>CN</given-names></name><name><surname>Alsner</surname><given-names>J</given-names></name><name><surname>Overgaard</surname><given-names>J</given-names></name></person-group>
<year>2002</year>
<article-title>Does variability in normal tissue reactions after radiotherapy have a genetic basis&#x02014;where and how to look for it?</article-title>
<source>Radiother Oncol</source>
<volume>64</volume>
<fpage>131</fpage>
<lpage>140</lpage>
<pub-id pub-id-type="pmid">12242122</pub-id></element-citation></ref><ref id="pone.0012402-Andreassen3"><label>15</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Andreassen</surname><given-names>CN</given-names></name><name><surname>Alsner</surname><given-names>J</given-names></name><name><surname>Overgaard</surname><given-names>J</given-names></name><name><surname>Herskind</surname><given-names>C</given-names></name><name><surname>Haviland</surname><given-names>J</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer.</article-title>
<source>Radiother Oncol</source>
<volume>75</volume>
<fpage>18</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="pmid">15878096</pub-id></element-citation></ref><ref id="pone.0012402-Finkelstein1"><label>16</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Finkelstein</surname><given-names>JN</given-names></name><name><surname>Johnston</surname><given-names>CJ</given-names></name><name><surname>Baggs</surname><given-names>R</given-names></name><name><surname>Rubin</surname><given-names>P</given-names></name></person-group>
<year>1994</year>
<article-title>Early alterations in extracellular matrix and transforming growth factor beta gene expression in mouse lung indicative of late radiation fibrosis.</article-title>
<source>Int J Radiat Oncol Biol Phys</source>
<volume>28</volume>
<fpage>621</fpage>
<lpage>631</lpage>
<pub-id pub-id-type="pmid">8113105</pub-id></element-citation></ref><ref id="pone.0012402-Quarmby1"><label>17</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Quarmby</surname><given-names>S</given-names></name><name><surname>Fakhoury</surname><given-names>H</given-names></name><name><surname>Levine</surname><given-names>E</given-names></name><name><surname>Barber</surname><given-names>J</given-names></name><name><surname>Wylie</surname><given-names>J</given-names></name><etal/></person-group>
<year>2003</year>
<article-title>Association of transforming growth factor beta-1 single nucleotide polymorphisms with radiation-induced damage to normal tissues in breast cancer patients.</article-title>
<source>Int J Radiat Biol</source>
<volume>79</volume>
<fpage>137</fpage>
<lpage>143</lpage>
<pub-id pub-id-type="pmid">12569017</pub-id></element-citation></ref><ref id="pone.0012402-Kiszel1"><label>18</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kiszel</surname><given-names>P</given-names></name><name><surname>Mako</surname><given-names>V</given-names></name><name><surname>Prohaszka</surname><given-names>Z</given-names></name><name><surname>Cervenak</surname><given-names>L</given-names></name></person-group>
<year>2007</year>
<article-title>Interleukin-6 -174 promoter polymorphism does not influence IL-6 production after LPS and IL-1 beta stimulation in human umbilical cord vein endothelial cells.</article-title>
<source>Cytokine</source>
<volume>40</volume>
<fpage>17</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="pmid">17869127</pub-id></element-citation></ref><ref id="pone.0012402-Terry1"><label>19</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Terry</surname><given-names>CF</given-names></name><name><surname>Loukaci</surname><given-names>V</given-names></name><name><surname>Green</surname><given-names>FR</given-names></name></person-group>
<year>2000</year>
<article-title>Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation.</article-title>
<source>J Biol Chem</source>
<volume>275</volume>
<fpage>18138</fpage>
<lpage>18144</lpage>
<pub-id pub-id-type="pmid">10747905</pub-id></element-citation></ref><ref id="pone.0012402-Huth1"><label>20</label><element-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Huth</surname><given-names>C</given-names></name><name><surname>Illig</surname><given-names>T</given-names></name><name><surname>Herder</surname><given-names>C</given-names></name><name><surname>Gieger</surname><given-names>C</given-names></name><name><surname>Grallert</surname><given-names>H</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>Joint analysis of individual participants' data from 17 studies on the association of the IL6 variant -174G &#x0003e;C with circulating glucose levels, interleukin-6 levels, and body mass index.</article-title>
<source>Ann Med</source>
<fpage>1</fpage>
<lpage>21</lpage>
</element-citation></ref><ref id="pone.0012402-Gao1"><label>21</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gao</surname><given-names>LB</given-names></name><name><surname>Rao</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>YY</given-names></name><name><surname>Liang</surname><given-names>WB</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>The association of interleukin-16 polymorphisms with IL-16 serum levels and risk of colorectal and gastric cancer.</article-title>
<source>Carcinogenesis</source>
<volume>30</volume>
<fpage>295</fpage>
<lpage>299</lpage>
<pub-id pub-id-type="pmid">19073878</pub-id></element-citation></ref><ref id="pone.0012402-Hill1"><label>22</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hill</surname><given-names>MR</given-names></name><name><surname>Papafili</surname><given-names>A</given-names></name><name><surname>Booth</surname><given-names>H</given-names></name><name><surname>Lawson</surname><given-names>P</given-names></name><name><surname>Hubner</surname><given-names>M</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>Functional prostaglandin-endoperoxide synthase 2 polymorphism predicts poor outcome in sarcoidosis.</article-title>
<source>Am J Respir Crit Care Med</source>
<volume>174</volume>
<fpage>915</fpage>
<lpage>922</lpage>
<pub-id pub-id-type="pmid">16840740</pub-id></element-citation></ref><ref id="pone.0012402-Papafili1"><label>23</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Papafili</surname><given-names>A</given-names></name><name><surname>Hill</surname><given-names>MR</given-names></name><name><surname>Brull</surname><given-names>DJ</given-names></name><name><surname>McAnulty</surname><given-names>RJ</given-names></name><name><surname>Marshall</surname><given-names>RP</given-names></name><etal/></person-group>
<year>2002</year>
<article-title>Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response.</article-title>
<source>Arterioscler Thromb Vasc Biol</source>
<volume>22</volume>
<fpage>1631</fpage>
<lpage>1636</lpage>
<pub-id pub-id-type="pmid">12377741</pub-id></element-citation></ref><ref id="pone.0012402-Dixon1"><label>24</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dixon</surname><given-names>DA</given-names></name></person-group>
<year>2004</year>
<article-title>Dysregulated post-transcriptional control of COX-2 gene expression in cancer.</article-title>
<source>Curr Pharm Des</source>
<volume>10</volume>
<fpage>635</fpage>
<lpage>646</lpage>
<pub-id pub-id-type="pmid">14965326</pub-id></element-citation></ref><ref id="pone.0012402-Hershey1"><label>25</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hershey</surname><given-names>GK</given-names></name><name><surname>Friedrich</surname><given-names>MF</given-names></name><name><surname>Esswein</surname><given-names>LA</given-names></name><name><surname>Thomas</surname><given-names>ML</given-names></name><name><surname>Chatila</surname><given-names>TA</given-names></name></person-group>
<year>1997</year>
<article-title>The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor.</article-title>
<source>N Engl J Med</source>
<volume>337</volume>
<fpage>1720</fpage>
<lpage>1725</lpage>
<pub-id pub-id-type="pmid">9392697</pub-id></element-citation></ref><ref id="pone.0012402-Crawley1"><label>26</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Crawley</surname><given-names>E</given-names></name><name><surname>Kay</surname><given-names>R</given-names></name><name><surname>Sillibourne</surname><given-names>J</given-names></name><name><surname>Patel</surname><given-names>P</given-names></name><name><surname>Hutchinson</surname><given-names>I</given-names></name><etal/></person-group>
<year>1999</year>
<article-title>Polymorphic haplotypes of the interleukin-10 5&#x02032; flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis.</article-title>
<source>Arthritis Rheum</source>
<volume>42</volume>
<fpage>1101</fpage>
<lpage>1108</lpage>
<pub-id pub-id-type="pmid">10366102</pub-id></element-citation></ref><ref id="pone.0012402-Gasche1"><label>27</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gasche</surname><given-names>C</given-names></name><name><surname>Grundtner</surname><given-names>P</given-names></name><name><surname>Zwirn</surname><given-names>P</given-names></name><name><surname>Reinisch</surname><given-names>W</given-names></name><name><surname>Shaw</surname><given-names>SH</given-names></name><etal/></person-group>
<year>2003</year>
<article-title>Novel variants of the IL-10 receptor 1 affect inhibition of monocyte TNF-alpha production.</article-title>
<source>J Immunol</source>
<volume>170</volume>
<fpage>5578</fpage>
<lpage>5582</lpage>
<pub-id pub-id-type="pmid">12759436</pub-id></element-citation></ref><ref id="pone.0012402-Dominici1"><label>28</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dominici</surname><given-names>R</given-names></name><name><surname>Cattaneo</surname><given-names>M</given-names></name><name><surname>Malferrari</surname><given-names>G</given-names></name><name><surname>Archi</surname><given-names>D</given-names></name><name><surname>Mariani</surname><given-names>C</given-names></name><etal/></person-group>
<year>2002</year>
<article-title>Cloning and functional analysis of the allelic polymorphism in the transcription regulatory region of interleukin-1 alpha.</article-title>
<source>Immunogenetics</source>
<volume>54</volume>
<fpage>82</fpage>
<lpage>86</lpage>
<pub-id pub-id-type="pmid">12037600</pub-id></element-citation></ref><ref id="pone.0012402-Kawaguchi1"><label>29</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kawaguchi</surname><given-names>Y</given-names></name><name><surname>Tochimoto</surname><given-names>A</given-names></name><name><surname>Hara</surname><given-names>M</given-names></name><name><surname>Kawamoto</surname><given-names>M</given-names></name><name><surname>Sugiura</surname><given-names>T</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Contribution of single nucleotide polymorphisms of the IL1A gene to the cleavage of precursor IL-1alpha and its transcription activity.</article-title>
<source>Immunogenetics</source>
<volume>59</volume>
<fpage>441</fpage>
<lpage>448</lpage>
<pub-id pub-id-type="pmid">17440718</pub-id></element-citation></ref><ref id="pone.0012402-Hull1"><label>30</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hull</surname><given-names>J</given-names></name><name><surname>Thomson</surname><given-names>A</given-names></name><name><surname>Kwiatkowski</surname><given-names>D</given-names></name></person-group>
<year>2000</year>
<article-title>Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families.</article-title>
<source>Thorax</source>
<volume>55</volume>
<fpage>1023</fpage>
<lpage>1027</lpage>
<pub-id pub-id-type="pmid">11083887</pub-id></element-citation></ref><ref id="pone.0012402-Kabesch1"><label>31</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kabesch</surname><given-names>M</given-names></name><name><surname>Tzotcheva</surname><given-names>I</given-names></name><name><surname>Carr</surname><given-names>D</given-names></name><name><surname>Hofler</surname><given-names>C</given-names></name><name><surname>Weiland</surname><given-names>SK</given-names></name><etal/></person-group>
<year>2003</year>
<article-title>A complete screening of the IL4 gene: novel polymorphisms and their association with asthma and IgE in childhood.</article-title>
<source>J Allergy Clin Immunol</source>
<volume>112</volume>
<fpage>893</fpage>
<lpage>898</lpage>
<pub-id pub-id-type="pmid">14610476</pub-id></element-citation></ref><ref id="pone.0012402-Vladich1"><label>32</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vladich</surname><given-names>FD</given-names></name><name><surname>Brazille</surname><given-names>SM</given-names></name><name><surname>Stern</surname><given-names>D</given-names></name><name><surname>Peck</surname><given-names>ML</given-names></name><name><surname>Ghittoni</surname><given-names>R</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>IL-13 R130Q, a common variant associated with allergy and asthma, enhances effector mechanisms essential for human allergic inflammation.</article-title>
<source>J Clin Invest</source>
<volume>115</volume>
<fpage>747</fpage>
<lpage>754</lpage>
<pub-id pub-id-type="pmid">15711639</pub-id></element-citation></ref><ref id="pone.0012402-Cameron1"><label>33</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cameron</surname><given-names>L</given-names></name><name><surname>Webster</surname><given-names>RB</given-names></name><name><surname>Strempel</surname><given-names>JM</given-names></name><name><surname>Kiesler</surname><given-names>P</given-names></name><name><surname>Kabesch</surname><given-names>M</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>Th2 cell-selective enhancement of human IL13 transcription by IL13-1112C&#x0003e;T, a polymorphism associated with allergic inflammation.</article-title>
<source>J Immunol</source>
<volume>177</volume>
<fpage>8633</fpage>
<lpage>8642</lpage>
<pub-id pub-id-type="pmid">17142763</pub-id></element-citation></ref><ref id="pone.0012402-Hohjoh1"><label>34</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hohjoh</surname><given-names>H</given-names></name><name><surname>Tokunaga</surname><given-names>K</given-names></name></person-group>
<year>2001</year>
<article-title>Allele-specific binding of the ubiquitous transcription factor OCT-1 to the functional single nucleotide polymorphism (SNP) sites in the tumor necrosis factor-alpha gene (TNFA) promoter.</article-title>
<source>Genes Immun</source>
<volume>2</volume>
<fpage>105</fpage>
<lpage>109</lpage>
<pub-id pub-id-type="pmid">11393654</pub-id></element-citation></ref><ref id="pone.0012402-Higuchi1"><label>35</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Higuchi</surname><given-names>T</given-names></name><name><surname>Seki</surname><given-names>N</given-names></name><name><surname>Kamizono</surname><given-names>S</given-names></name><name><surname>Yamada</surname><given-names>A</given-names></name><name><surname>Kimura</surname><given-names>A</given-names></name><etal/></person-group>
<year>1998</year>
<article-title>Polymorphism of the 5&#x02032;-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese.</article-title>
<source>Tissue Antigens</source>
<volume>51</volume>
<fpage>605</fpage>
<lpage>612</lpage>
<pub-id pub-id-type="pmid">9694352</pub-id></element-citation></ref><ref id="pone.0012402-Lv1"><label>36</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lv</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Cai</surname><given-names>Q</given-names></name><name><surname>Fang</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name></person-group>
<year>2006</year>
<article-title>Effects of a single nucleotide polymorphism on the expression of human tumor necrosis factor-alpha.</article-title>
<source>Scand J Immunol</source>
<volume>64</volume>
<fpage>164</fpage>
<lpage>169</lpage>
<pub-id pub-id-type="pmid">16867162</pub-id></element-citation></ref><ref id="pone.0012402-Soga1"><label>37</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Soga</surname><given-names>Y</given-names></name><name><surname>Nishimura</surname><given-names>F</given-names></name><name><surname>Ohyama</surname><given-names>H</given-names></name><name><surname>Maeda</surname><given-names>H</given-names></name><name><surname>Takashiba</surname><given-names>S</given-names></name><etal/></person-group>
<year>2003</year>
<article-title>Tumor necrosis factor-alpha gene (TNF-alpha) -1031/-863, -857 single-nucleotide polymorphisms (SNPs) are associated with severe adult periodontitis in Japanese.</article-title>
<source>J Clin Periodontol</source>
<volume>30</volume>
<fpage>524</fpage>
<lpage>531</lpage>
<pub-id pub-id-type="pmid">12795791</pub-id></element-citation></ref><ref id="pone.0012402-Puthothu1"><label>38</label><element-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Puthothu</surname><given-names>B</given-names></name><name><surname>Bierbaum</surname><given-names>S</given-names></name><name><surname>Kopp</surname><given-names>MV</given-names></name><name><surname>Forster</surname><given-names>J</given-names></name><name><surname>Heinze</surname><given-names>J</given-names></name><etal/></person-group>
<year>2008</year>
<article-title>Association of TNF-alpha with severe respiratory syncytial virus infection and bronchial asthma.</article-title>
<source>Pediatr Allergy Immunol</source>
</element-citation></ref><ref id="pone.0012402-Sato1"><label>39</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sato</surname><given-names>H</given-names></name><name><surname>Silveira</surname><given-names>L</given-names></name><name><surname>Fingerlin</surname><given-names>T</given-names></name><name><surname>Dockstader</surname><given-names>K</given-names></name><name><surname>Gillespie</surname><given-names>M</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>TNF polymorphism and bronchoalveolar lavage cell TNF-alpha levels in chronic beryllium disease and beryllium sensitization.</article-title>
<source>J Allergy Clin Immunol</source>
<volume>119</volume>
<fpage>687</fpage>
<lpage>696</lpage>
<pub-id pub-id-type="pmid">17208287</pub-id></element-citation></ref><ref id="pone.0012402-vanHeel1"><label>40</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>van Heel</surname><given-names>DA</given-names></name><name><surname>Udalova</surname><given-names>IA</given-names></name><name><surname>De Silva</surname><given-names>AP</given-names></name><name><surname>McGovern</surname><given-names>DP</given-names></name><name><surname>Kinouchi</surname><given-names>Y</given-names></name><etal/></person-group>
<year>2002</year>
<article-title>Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF(-kappa)B transcription factors.</article-title>
<source>Hum Mol Genet</source>
<volume>11</volume>
<fpage>1281</fpage>
<lpage>1289</lpage>
<pub-id pub-id-type="pmid">12019209</pub-id></element-citation></ref><ref id="pone.0012402-Morita1"><label>41</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Morita</surname><given-names>C</given-names></name><name><surname>Horiuchi</surname><given-names>T</given-names></name><name><surname>Tsukamoto</surname><given-names>H</given-names></name><name><surname>Hatta</surname><given-names>N</given-names></name><name><surname>Kikuchi</surname><given-names>Y</given-names></name><etal/></person-group>
<year>2001</year>
<article-title>Association of tumor necrosis factor receptor type II polymorphism 196R with Systemic lupus erythematosus in the Japanese: molecular and functional analysis.</article-title>
<source>Arthritis Rheum</source>
<volume>44</volume>
<fpage>2819</fpage>
<lpage>2827</lpage>
<pub-id pub-id-type="pmid">11762942</pub-id></element-citation></ref><ref id="pone.0012402-Till1"><label>42</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Till</surname><given-names>A</given-names></name><name><surname>Rosenstiel</surname><given-names>P</given-names></name><name><surname>Krippner-Heidenreich</surname><given-names>A</given-names></name><name><surname>Mascheretti-Croucher</surname><given-names>S</given-names></name><name><surname>Croucher</surname><given-names>PJ</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>The Met-196 -&#x0003e; Arg variation of human tumor necrosis factor receptor 2 (TNFR2) affects TNF-alpha-induced apoptosis by impaired NF-kappaB signaling and target gene expression.</article-title>
<source>J Biol Chem</source>
<volume>280</volume>
<fpage>5994</fpage>
<lpage>6004</lpage>
<pub-id pub-id-type="pmid">15572357</pub-id></element-citation></ref><ref id="pone.0012402-Wang2"><label>43</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>XL</given-names></name><name><surname>Sim</surname><given-names>AS</given-names></name><name><surname>Wang</surname><given-names>MX</given-names></name><name><surname>Murrell</surname><given-names>GA</given-names></name><name><surname>Trudinger</surname><given-names>B</given-names></name><etal/></person-group>
<year>2000</year>
<article-title>Genotype dependent and cigarette specific effects on endothelial nitric oxide synthase gene expression and enzyme activity.</article-title>
<source>FEBS Lett</source>
<volume>471</volume>
<fpage>45</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="pmid">10760510</pub-id></element-citation></ref><ref id="pone.0012402-Veldman1"><label>44</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Veldman</surname><given-names>BA</given-names></name><name><surname>Spiering</surname><given-names>W</given-names></name><name><surname>Doevendans</surname><given-names>PA</given-names></name><name><surname>Vervoort</surname><given-names>G</given-names></name><name><surname>Kroon</surname><given-names>AA</given-names></name><etal/></person-group>
<year>2002</year>
<article-title>The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide.</article-title>
<source>J Hypertens</source>
<volume>20</volume>
<fpage>2023</fpage>
<lpage>2027</lpage>
<pub-id pub-id-type="pmid">12359981</pub-id></element-citation></ref><ref id="pone.0012402-Trotti1"><label>45</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Trotti</surname><given-names>A</given-names></name><name><surname>Colevas</surname><given-names>AD</given-names></name><name><surname>Setser</surname><given-names>A</given-names></name><name><surname>Rusch</surname><given-names>V</given-names></name><name><surname>Jaques</surname><given-names>D</given-names></name><etal/></person-group>
<year>2003</year>
<article-title>CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.</article-title>
<source>Semin Radiat Oncol</source>
<volume>13</volume>
<fpage>176</fpage>
<lpage>181</lpage>
<pub-id pub-id-type="pmid">12903007</pub-id></element-citation></ref><ref id="pone.0012402-Engels1"><label>46</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Engels</surname><given-names>EA</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Dong</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer.</article-title>
<source>Cancer Res</source>
<volume>67</volume>
<fpage>6520</fpage>
<lpage>6527</lpage>
<pub-id pub-id-type="pmid">17596594</pub-id></element-citation></ref><ref id="pone.0012402-Storey1"><label>47</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Storey</surname><given-names>JD</given-names></name></person-group>
<year>2002</year>
<article-title>A direct approch to false discovery rates.</article-title>
<source>J R Stat Soc B</source>
<volume>64</volume>
<fpage>479</fpage>
<lpage>498</lpage>
</element-citation></ref></ref-list></back></article>